

# US Patent & Trademark Office

## Patent Public Search | Text View

---

United States Patent	12384823
Kind Code	B2
Date of Patent	August 12, 2025
Inventor(s)	Lin; Zhiqiang

---

### Vgll4 with Ucp-1 cis-regulatory element and method of use thereof

---

#### Abstract

Provided is a polynucleotide, including a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein, wherein the cis-regulatory element includes an uncoupling protein 1 enhancer and an uncoupling protein 1 promoter. Also provided is a viral vector including said polynucleotide. Also provided is a method of transfecting a cell or a subject with said polynucleotide or said viral vector.

---

<b>Inventors:</b>	<b>Lin; Zhiqiang (Utica, NY)</b>
<b>Applicant:</b>	<b>MASONIC MEDICAL RESEARCH LABORATORY (Utica, NY)</b>
<b>Family ID:</b>	<b>1000008750813</b>
<b>Assignee:</b>	<b>MASONIC MEDICAL RESEARCH LABORATORY (Utica, NY)</b>
<b>Appl. No.:</b>	<b>17/731201</b>
<b>Filed:</b>	<b>April 27, 2022</b>

#### Prior Publication Data

<b>Document Identifier</b>	<b>Publication Date</b>
US 20220259276 A1	Aug. 18, 2022

#### Related U.S. Application Data

continuation parent-doc US 16925632 20200710 US 11319354 child-doc US 17731201  
us-provisional-application US 62872624 20190710

---

#### Publication Classification

**Int. Cl.:** C07K14/47 (20060101); C12N15/86 (20060101)

## U.S. Cl.:

CPC     **C07K14/4705** (20130101); **C12N15/86** (20130101); C12N2750/14143 (20130101);  
C12N2830/001 (20130101)

## Field of Classification Search

**CPC:**     C07K (14/4705); C07K (14/4702); C12N (15/86); C12N (2750/14143); C12N  
(2830/001); C12N (2830/008); A61K (48/0058); A01K (2207/25); A01K (2227/105);  
A01K (2267/0362)

---

## References Cited

### U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
5139941	12/1991	Muzyczka et al.	N/A	N/A
5436146	12/1994	Shenk et al.	N/A	N/A
5446143	12/1994	Simpson et al.	N/A	N/A
5464758	12/1994	Gossen et al.	N/A	N/A
5478745	12/1994	Samulski et al.	N/A	N/A
5741683	12/1997	Zhou et al.	N/A	N/A
6001650	12/1998	Colosi	N/A	N/A
6057152	12/1999	Samulski et al.	N/A	N/A
6136597	12/1999	Hope et al.	N/A	N/A
6156303	12/1999	Russell et al.	N/A	N/A
6165782	12/1999	Naldini et al.	N/A	N/A
6204059	12/2000	Samulski et al.	N/A	N/A
6207455	12/2000	Chang	N/A	N/A
6218181	12/2000	Verma et al.	N/A	N/A
6268213	12/2000	Samulski et al.	N/A	N/A
6277633	12/2000	Olsen	N/A	N/A
6323031	12/2000	Cichutek	N/A	N/A
6358732	12/2001	Sedlacek et al.	N/A	N/A
6432705	12/2001	Yee et al.	N/A	N/A
6491907	12/2001	Rabinowitz et al.	N/A	N/A
6531456	12/2002	Kurtzman et al.	N/A	N/A
6596535	12/2002	Carter	N/A	N/A
6660514	12/2002	Zolotukhin et al.	N/A	N/A
6951753	12/2004	Shenk et al.	N/A	N/A
7056502	12/2005	Hildinger et al.	N/A	N/A
7094604	12/2005	Snyder et al.	N/A	N/A
7125717	12/2005	Carter	N/A	N/A
7172893	12/2006	Rabinowitz et al.	N/A	N/A
7198951	12/2006	Gao et al.	N/A	N/A
7201898	12/2006	Monahan et al.	N/A	N/A
7220577	12/2006	Zolotukhin	N/A	N/A
7229823	12/2006	Samulski et al.	N/A	N/A
7235393	12/2006	Gao et al.	N/A	N/A
7282199	12/2006	Gao et al.	N/A	N/A

7319002	12/2007	Wilson et al.	N/A	N/A
7439065	12/2007	Ferrari et al.	N/A	N/A
7456683	12/2007	Takano et al.	N/A	N/A
7790449	12/2009	Gao et al.	N/A	N/A
8455204	12/2012	Boss et al.	N/A	N/A
8852939	12/2013	Hall et al.	N/A	N/A
9034839	12/2014	Thibonnier	N/A	N/A
2002/0065239	12/2001	Caplan et al.	N/A	N/A
2002/0076395	12/2001	Crystal et al.	N/A	N/A
2003/0138772	12/2002	Gao et al.	N/A	N/A
2003/0148506	12/2002	Kotin et al.	N/A	N/A
2003/0219409	12/2002	Coffin et al.	N/A	N/A
2004/0055023	12/2003	Gao et al.	N/A	N/A
2005/0187154	12/2004	Kahn et al.	N/A	N/A
2008/0075740	12/2007	Gao et al.	N/A	N/A
2010/0216709	12/2009	Scheule et al.	N/A	N/A
2010/0240029	12/2009	Guarente et al.	N/A	N/A
2011/0166210	12/2010	Felber et al.	N/A	N/A
2012/0040401	12/2011	Ellis et al.	N/A	N/A
2016/0319303	12/2015	Jiménez Cenzano et al.	N/A	N/A
2017/0290926	12/2016	Smith et al.	N/A	N/A
2021/0009646	12/2020	Lin	N/A	N/A
2021/0017606	12/2020	Li et al.	N/A	N/A

#### FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
104548131	12/2018	CN	N/A
1995309	12/2007	EP	N/A
2394667	12/2010	EP	N/A
2492347	12/2011	EP	N/A
3101125	12/2015	EP	N/A
1996040954	12/1995	WO	N/A
199749827	12/1996	WO	N/A
1997049827	12/1996	WO	N/A
1998009524	12/1997	WO	N/A
1998011244	12/1997	WO	N/A
1999061601	12/1998	WO	N/A
2000028061	12/1999	WO	N/A
2001083692	12/2000	WO	N/A
2001091803	12/2000	WO	N/A
2001094605	12/2000	WO	N/A
2003014367	12/2002	WO	N/A
2003042397	12/2002	WO	N/A
2003052051	12/2002	WO	N/A
2003052052	12/2002	WO	N/A
2006110689	12/2005	WO	N/A
2007127264	12/2006	WO	N/A
2008021290	12/2007	WO	N/A
2008103755	12/2007	WO	N/A
2010010887	12/2009	WO	N/A

2011154520	12/2010	WO	N/A
2012007458	12/2011	WO	N/A
2013063379	12/2012	WO	N/A
2014023808	12/2013	WO	N/A
2015173308	12/2014	WO	N/A
2016193431	12/2015	WO	N/A
2017127750	12/2016	WO	N/A
2018060097	12/2017	WO	N/A
2018215613	12/2017	WO	N/A

## OTHER PUBLICATIONS

Zhang, Y., et al., "A growing role for the Hippo signaling pathway in the hear: Hippo pathway function in the heart," *Journal of Molecular Medicine*, vol. 95, No. 5, pp. 465-472 (2018). cited by applicant

Zhang et al., "The TEA domain family transcription factor TEAD4 represses murine adipogenesis by recruiting the cofactors VGLL4 and CtBP2 into a transiptional complex", *Journal of Biological Chemistry*, vol. 293, No. 44, pp. 17119-17134, Sep. 12, 2018. cited by applicant

Cassard, A., et al., "Human Uncoupling Protein Gene: Structure, Comparison With Rat Gene, and Assignment to the Long Arm of Chromosome 4", *Journal of Cellular Biochemistry*, vol. 43, pp. 255-264 (1990). cited by applicant

Jiao, S., et al., "A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer", *Cancer Cell*, vol. 25, pp. 166-180 (2014). cited by applicant

Gonzalez-Barroso, M., et al., "Transcriptional Activation of the Human ucp1 Gene in a Rodent Cell Line", *The Journal of Biological Chemistry*, vol. 275, No. 41, pp. 31722-31732 (2000). cited by applicant

Deng, X., et al., "VGLL4 is a transcriptional cofactor acting as a novel tumor suppressor via interacting with TEADs", *Am J Cancer Res*, vol. 8, No. 6, pp. 932-943 (2018). cited by applicant

"Minutes of the 48th General Assembly of the European Association for the Study of Diabetes", *Diabetologia*, vol. 56, Suppl 1, S1 and S319 (2013). cited by applicant

Cassard-Doulcier, A., et al., "A 211-bp enhancer of the rat uncoupling protein-1 (UCP-1) gene controls specific and regulated expression in brown adipose tissue", *Biochem. J.*, vol. 333, pp. 243-246 (1998). cited by applicant

Chen, H., et al., "Vgl-4, a Novel Member of the Vestigial-like Family of Transcription Cofactors, Regulates  $\alpha$ 1-Adrenergic Activation of Gene Expression in Cardiac Myocytes", *The Journal of Biological Chemistry*, vol. 279, No. 29, pp. 30800-30806 (2004). cited by applicant

Kozak, U.C., et al., "An Upstream Enhancer Regulating Brown-Fat-Specific Expression of the Mitochondrial Uncoupling Protein Gene", *Molecular and Cellular Biology*, vol. 14, No. 1, pp. 59-67 (1994). cited by applicant

Larose, M., et al., "Essential cis-Acting Elements in Rat Uncoupling Protein Gene Are in an Enhancer Containing a Complex Retinoic Acid Response Domain", vol. 271, No. 49, pp. 31533-31542 (1996). cited by applicant

Rim, J.S., et al., "Regulatory Motifs for CREB-binding Protein and Nfe212 Transcription Factors in the Upstream Enhancer of the Mitochondrial Uncoupling Protein 1 Gene", *The Journal of Biological Chemistry*, vol. 277, No. 37, pp. 34589-34600 (2002). cited by applicant

Shore, A., et al., "Role of Ucp1 enhancer methylation and chromatin remodelling in the control of Ucp1 expression in murine adipose tissue", *Diabetologia*, vol. 53, pp. 1164-1173 (2010). cited by applicant

Skarnes, W.C., et al., "A conditional knockout resource for the genome-wide study of mouse gene function", *Nature*, vol. 474, pp. 337-344 (2011). cited by applicant

Gao et al., "Computational insights into the interaction mechanism of transcription cofactor

vestigial-like protein 4 binding to TEA domain transcription factor 4 by molecular dynamics simulation and molecular mechanics generalized Born/surface area) calculation”, *Journal of Biomolecular Structure & Dynamics*, vol. 37, No. 10, pp. 2538-2545, Nov. 9, 2018. cited by applicant

Jiao et al. (2014), A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer, *Cancer Cell*, 25:166-180. cited by applicant

Monahan et al., “AAV vectors: is clinical success on the horizon?” *Gene Therapy*, 2000, vol. 7: pp. 24-30. cited by applicant

Gonzalez-Barroso et al., Transcriptional Activation of the Human ucp 1 Gene in a rodent cell line: synergism of retinoid, isoproterenol and thiazolidinedione is mediated by a multipartite response element, *The Journal of Biological Chemistry*, 2000, vol. 275(41): pp. 31722-31732. cited by applicant

Ahi et al., “Adenoviral Vector Immunity: its implication and circumvention strategies,” *Current Gene Therapy*, 2011, vol. 11(4): pp. 307-320. cited by applicant

Donello et al., “Woodchuck Hepatitis Virus Contains a Tripartite Postranscriptional Regulatory Element,” *Journal of Virology*, 1998, vol. 72(6): pp. 5085-5092. cited by applicant

Al-Dosari et al., “Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver,” *Biochemical and Biophysical Research Communication*, 2006, vol. 339(2): pp. 673-678. cited by applicant

Zhang et al., “Celastrol enhances AAV1-mediated gene expression in mice adipose tissues,” *Gene Therapy*, 2011, vol. 18(2): pp. 128-134. cited by applicant

Gao et al., Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues. *Journal of Virology*, 2004 vol. 78: pp. 6381-6388. cited by applicant

Graves et al., Analysis of a Tissue-Specific Enhancer: ARF6 Regulates Adipogenic Gene Expression. *Molecular and Cellular Biology*, 1992, vol. 12(3): pp. 202-1208. cited by applicant

Amado et al., Lentiviral Vectors—the Promise of Gene Therapy Within Reach?, *Science*, 1999, vol. 285: pp. 674-676. cited by applicant

Graves et al., “Identification of a potent adipocyte-specific enhancer: involvement of an NF-1-like factor,” *Genes & Development*, 1991, vol. 5(3): pp. 428-437. cited by applicant

Mizukami et al., “Adipose Tissue as a Novel Target for In Vivo Gene Transfer by Adeno-Associated Viral Vectors,” *Human Gene Therapy*, 2006, vol. 17: pp. 921-928. cited by applicant

Apparailly et al., “Adeno-Associated Virus Pseudotype 5 Vector Improves Gene Transfer in Arthritic Joints,” *Human Gene Therapy*, 2005, vol. 16(4): pp. 426-434. cited by applicant

Ayuso et al., Production, Purification and Characterization of Adeno-Associated Vectors, *Current Gene Therapy*, 2010, vol. 10: pp. 423-436. cited by applicant

Kitajima et al., “Persistent liver expression of murine apoA-I using vectors based on adeno-associated viral vectors serotypes 5 and 1,” *Atherosclerosis*, 2006, vol. 186: pp. 65-73. cited by applicant

Kozak et al., An Upstream Enhancer Regulating Brown-Fat Specific Expression of Mitochondrial Uncoupling Protein Gene, *Molecular and Cellular Biology*, 1994, vol. 14: pp. 59-67. cited by applicant

Leherz et al., “Novel AAV serotypes for improved ocular gene transfer,” *The Journal of Gene Medicine*, 2008, vol. 10: pp. 375-382. cited by applicant

Lee et al. “Optimizing regulatable gene expression using adenoviral vectors,” *Experimental Physiology*, 2004, vol. 90: pp. 33-37. cited by applicant

Liu et al., “Promoter effects of adeno-associated viral vector for transgene expression in the cochlea in vivo,” *Experimental and Molecular Medicine*, 2007, vol. 39: pp. 170-175, 2007. cited by applicant

Lock et al., “Characterization of a Recombinant Adeno-Associated Virus Type 2 Reference Standard Material,” *Human Gene Therapy*, 2010, vol. 21: pp. 1273-1285. cited by applicant

Mori et al., "Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein," *Virology*, 2004, vol. 330: pp. 375-383. cited by applicant

Muise et al., "Adipose Fibroblast Growth Factor 21 is Up-Regulated by Peroxisome Proliferator-Activated Receptor gamma and Altered Metabolic States," *Molecular Pharmacology*, 2008, vol. 74: pp. 403-412. cited by applicant

Okada et al., Scalable Purification of Adeno-Associated Virus Serotype 1 (AAV1) and AAV8 Vectors, Using Dual Ion-Exchange Adsorptive Membranes, *Human Gene Therapy*, 2009, vol. 20: pp. 1013-1021. cited by applicant

Rabinowitz et al., "Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity," 2002, vol. 76(2): pp. 791-801. cited by applicant

Bish et al., "Adeno-Associated Virus (AAV) Serotype 9 Provides Global Cardiac Gene Transfer Superior to AAV1, AAV6, AAV7, and AAV8 in the Mouse and Rat," *Human Gene Therapy*, 2008, vol. 19(12): pp. 1359-1368. cited by applicant

Rival et al., "Human Adipocyte Fatty Acid-Binding Protein (aP2) Gene Promoter-Driven Reporter Assay Discriminates Nonlipogenic Peroxisomes Proliferator-Activated Receptor gamma Ligands," *The Journal of Pharmacology and Experimental Therapeutics*, 2004, vol. 311(2): pp. 467-475. cited by applicant

Ross et al., "A fat-specific enhancer is the primary determinant of gene expression for adipocyte P2 in vivo," *Proceedings of the National Academy of the Sciences of the United States of America*, 1990, vol. 87: pp. 9590-9594. cited by applicant

Seale et al., "Prdm 16 determines the thermogenic program of subcutaneous white adipose tissue in mice," *The Journal of Clinical Investigation*, 2011, vol. 121(1): pp. 96-105. cited by applicant

Boshart et al., "A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus," *Cell*, 1985, vol. 41: pp. 521-530. cited by applicant

Boulos et al., "Assessment of CMV, RSV and SYN1 promoters and the woodchuck post-transcriptional regulatory element in adenovirus vectors for transgene expression in cortical neuronal cultures," *Brain Research*, 2006, vol. 1102: pp. 27-38. cited by applicant

Boyer et al., "The Mitochondrial Uncoupling Protein Gene in Brown Fat: Correlation between DNase 1 Hypersensitivity and Expression in Transgenic Mice," *Molecular and Cellular Biology*, 1991, vol. 11: pp. 4147-4156. cited by applicant

Taymans et al., "Comparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7 and 8 in Mouse Brain," *Human Gene Therapy*, 2007, vol. 18: pp. 195-206. cited by applicant

Broekman et al., "Adeno-Associated Virus Vectors Serotypes With AAV8 Capsid Are More Efficient Than AAV1 Or -2 Serotypes for Widespread Gene Delivery to the Neonatal Mouse Brain," *Neuroscience*, 2006, vol. 138(2): pp. 501-510. cited by applicant

Urabe et al., "A novel dicistronic AAV vector using a short IRES segment derived from hepatitis C virus genome," *Gene*, 1997, vol. 200: pp. 157-162. cited by applicant

Wang et al., "Improved neuronal transgene expression from an AAV-2 vector with a hybrid CMV enhancer/PDGF-B promoter," *The Journal of Gene Medicine*, 2005, vol. 7: pp. 945-955. cited by applicant

Wu et al., "Effect of Genome Size on AAV Vector Packaging," *Molecular Therapy*, 2010, vol. 18(1): pp. 80-86. cited by applicant

Cao, "Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases," *Nature Reviews*, 2010, vol. 9: pp. 107-115. cited by applicant

Zarrin et al., "Comparison of CMV, RSV, SV40 viral and Vlambda 1 cellular promoters in B and T lymphoid and non-lymphoid cell lines," *Biochimica et Physica Acta*, 1999, vol. 1446: pp. 135-139. cited by applicant

Zincarelli et al., Analysis of AAV Serotypes 1-9 Mediated Gene Expression and Tropism in Mice After Systemic Injection. *Molecular Therapy*, 2008, vol. 16(6): pp. 1073-1080. cited by applicant

Zufferey et al., "Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances Expression of Transgenes Delivered by Retroviral Vectors," *Journal of Virology*, 1999, vol. 73: pp. 2886-2892. cited by applicant

Cassard-Doulcier et al., "A 211-bp enhancer of the rat uncoupling protein-1 (UCP-1) gene controls specific and regulated expression in brown adipose tissue," *Biochemical Journal*, 1998, vol. 333: pp. 243-246. cited by applicant

Casteilla Louise et al., "Virus-based gene transfer approaches and adipose tissue biology," *Current Gene Therapy*, 2008, vol. 8(2): pp. 79-87. cited by applicant

Ayuso et al., "High AAV vector purity results in serotype and tissue independent enhancement of transduction efficiency," *Gene Therapy*, 2010, vol. 17: pp. 503-510. cited by applicant

Chao et al., Several Log Increase in Therapeutic Transgene Delivery by Distinct Adeno-Associated Viral Serotype Vectors, *Molecular Therapy*, 2000, vol. 2(6): pp. 19-623. cited by applicant

Chlorini et al., "Cloning of Adeno-Associated Virus type 4 (AAV4) and Generation of Recombinant AAV4 Particles," *Journal of Virology*, 1997, vol. 71: pp. 6823-6833. cited by applicant

Daya et al., "Gene Therapy Using Adeno-Associated Virus Vectors," *Clinical Microbiology Reviews*, 2008, vol. 21(4): pp. 583-593. cited by applicant

Dressman, "AAV-Mediated Gene Transfer to Models of Muscular Dystrophy: Insights Into Assembly of Multi-Subunit Membrane Proteins," University of Pittsburgh, Graduate Faculty of the School of Medicine, Dept. of Biochemistry and Molecular Genetics in partial fulfillment of the requirements for the degree of Doctor of Philosophy. 1997, 183 pages. cited by applicant

Elais et al., Adipose Tissue Overexpression of Vascular Endothelial Growth Factor Protects Against Diet-Induced Obesity and Insulin Resistance, *Diabetes*, 2012, vol. 61: pp. 1801-1813. cited by applicant

Harms et al., "Brown and beige fat: development, function and therapeutic potential," *Nature Medicine*, 2013, vol. 19 (10): pp. 1252-1263. cited by applicant

Gustafson et al., Restricted Adipogenesis in Hypertrophic Obesity: The Role of WISP2, Wnt and BMP4, *Diabetes*, 2013, vol. 62(9): pp. 2297-3004. cited by applicant

Loeb et al., "Enhanced Expression of Transgenes from Adeno-Associated Virus Vectors with the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element: Implications for Gene Therapy." *Human Gene Therapy*, 1999, vol. 10: pp. 2295-2305. cited by applicant

Hoffman et al., "Increased BMP4 improves insulin sensitivity and increases beige/brown adipogenesis in adult mice. *Diabetologica*," vol. 57, Supp , S1-S566, Sep. 26, 2014. cited by applicant

Ichimura et al., "Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human," *Nature*, 2012, vol. 483: pp. 350-354. cited by applicant

Jimenez et al., "In Vivo Adeno-Associated Viral Vector Mediated Genetic Engineering of White and Brown Adipose Tissue in Adult Mice," *Diabetes*, 2013, vol. 62: pp. 4012-4022. cited by applicant

Kahn et al., "Mechanism linking obesity to insulin resistance and type 2 diabetes," *Nature*, 2006, vol. 444: pp. 840-846. cited by applicant

Yee et al., "Subcutaneous adipose tissue fatty acid desaturation in adults with and without rare adipose disorders," *Lipids in Health and Disease*, 2012, vol. 11: pp. 19-30. cited by applicant

Yu et al., "Protein deacetylation by SIRT 1: an emerging key post-translational modification in metabolic regulation," *Pharmacological Research*, 2010, vol. 62(1): pp. 35-41. cited by applicant

Qiao et al., "Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver," *Gene Therapy*, 2011, vol. 18: pp. 403-410. cited by applicant

Kelly et al., "Attenuation of Vesicular Stomatitis Virus Encephalitis through MicroRNA targeting," *Journal of Virology*, 2010, vol. 84(3): pp. 1550-1562. cited by applicant

Chen et al., "The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and

differentiation,” Nature Genetics, 2006, vol. 38: pp. 228-233. cited by applicant  
Zhang et al., “Adipose Tissue Transduction Using AAV8-based Vectors: Inadvertent Gene Transfer into Liver,” Molecular Therapy, 2005, vol. 11, supp 1, article 862. cited by applicant  
Yan et al., “Inverted Terminal Repeat Sequences are Important for Intermolecular Recombination and Circularization of Adeno-Associated Virus Genomes,” Journal of Virology, 2005, vol. 79: pp. 364-379. cited by applicant  
Card et al., MicroRNA Silencing Improves the Tumor Specificity of Adenoviral Transgene Expression, 2012, vol. 19: pp. 451-459. cited by applicant

---

*Primary Examiner:* Holland; Paul J

*Attorney, Agent or Firm:* Heslin Rothenberg Farley & Mesiti P.C.

---

## **Background/Summary**

CROSS-REFERENCE TO RELATED APPLICATIONS (1) This application is a continuation of U.S. patent application Ser. No. 16/925,632 which was filed on Jul. 10, 2022, published as US 2021/0009646 A1 on Jan. 14, 2021, and claims priority to U.S. Provisional Application No. 62/872,624, filed Jul. 10, 2019, the entire contents of which are incorporated herein in their entireties.

### **SEQUENCE LISTING**

(1) The instant application contains a Sequence Listing, created on Apr. 27, 2022; the file, in ASCII format, is designated H2341109 and is 65.9 KB in size. The file is hereby incorporated by reference in its entirety into the instant application.

### **BACKGROUND**

(2) Obesity is a global epidemic that plagues the human society, threatening the health of both adult and children. Effective pharmacological therapies for obesity are urgently needed. Obesity-related pathologies include, among others, diabetes and liver disease. Adipose tissue overgrowth is the root of obesity, with deleterious health effects. Adipose tissue is composed of white and brown adipose tissue (BAT). White adipose tissue (WAT) stores triglycerides in adipocytes, and BAT burns triglycerides and glucose for generating heat. The development of obesity depends not only on the balance between food intake and caloric utilization but also on the balance between BAT and WAT. Higher BAT is correlated with leanness in the adult and greater muscle volume in children, indicating that functional BAT benefits both energy homeostasis and muscle growth. In humans, BAT is abundant in infants, and decreases with age. Recently, the discovery of functional BAT in adult individuals raised the possibility of treating obesity by activating BAT. However, compositions and methods for increasing BAT are lacking. The present disclosure is directed to overcoming these and other deficiencies in the art.

### **SUMMARY**

(3) The following disclosure includes improvements over such shortcomings.

(4) In an aspect, provided is a polynucleotide, including a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein, wherein the cis-regulatory element includes an uncoupling protein 1 enhancer and an uncoupling protein 1 promoter. In an example, the uncoupling protein 1 enhancer has at least 90% identity with a sequence selected from SEQ ID NO: 1, SEQ ID NO 4, and SEQ ID NO: 7. In another example, the uncoupling protein 1 enhancer is selected from SEQ ID NO: 1, SEQ ID NO 4, and SEQ ID NO: 7. In another example, the uncoupling protein 1 promoter has at least 90% identity with a sequence selected from SEQ ID NO: 2, SEQ ID NO 5, and SEQ ID NO: 8. In still another example, the uncoupling protein 1



promotor is selected from SEQ ID NO: 2, SEQ ID NO 5, and SEQ ID NO: 8. In yet another example, the cis-regulatory element has at least 90% homology with a sequence selected from SEQ ID NO: 3, SEQ ID NO: 6, and SEQ ID NO: 9. In a further example, the cis-regulatory element is selected from SEQ ID NO: 3, SEQ ID NO: 6, and SEQ ID NO: 9.

(5) In another example, the vestigial like 4 protein has at least 90% homology with a sequence selected from SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, and SEQ ID NO: 33. In still another example, the vestigial like 4 protein is selected from SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, and SEQ ID NO: 33. In yet another example, the sequence encoding a vestigial like 4 protein has at least 90% identity with a sequence selected from SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, and SEQ ID NO: 32. In a further example, the sequence encoding a vestigial like 4 protein is selected from SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, and SEQ ID NO: 32.

(6) In another example, the vestigial like 4 protein has from 0 to 3 substitutions to a sequence selected from SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, and SEQ ID NO: 21, wherein the substitutions are not in a TDU domain. In still another example, the vestigial like 4 protein has from 0 to 3 substitutions to a sequence selected from SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, and SEQ ID NO: 33, wherein the substitutions are not in a TDU domain.

(7) Another example further includes an intron between the cis-regulatory element and the nucleotide sequence encoding a vestigial like 4 protein. In another example, the intron has at least 90% homology with SEQ ID NO: 34. In still another example, the intron is SEQ ID NO: 34.

(8) Another example includes a nucleotide sequence having at least 90% homology with SEQ ID NO: 35. An example includes a nucleotide sequence of SEQ ID NO: 35. Another example includes a nucleotide sequence having at least 90% homology with SEQ ID NO: 36. An example includes a nucleotide sequence of SEQ ID NO: 36.

(9) Another example further includes a nucleotide sequence encoding a reporter protein. In another example, the reporter protein is selected from a green fluorescent protein, a yellow fluorescent protein, a red fluorescent protein, a blue fluorescent protein, a luciferase protein, a beta-galactosidase protein, a glutathione S-transferase protein, a chloramphenicol acetyltransferase protein, and any combination of two or more of the foregoing. In still another example, the reporter protein includes a green fluorescent protein. In yet another example, the reporter protein includes SEQ ID NO: 37. In a further example, the nucleotide sequence encoding a reporter protein includes SEQ ID NO: 38.

(10) Another example includes a nucleotide sequence having at least 90% homology with SEQ ID NO: 39. An example includes SEQ ID NO: 39. Another example includes a nucleotide sequence having at least 90% homology with SEQ ID NO: 40. An example includes SEQ ID NO: 40.

(11) In another aspect, provided is a viral vector including any of the foregoing examples of a polynucleotide that include a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein. In an example, the viral vector includes an adenoviral associated vector.

(12) In another aspect, provided is a cell transfected with any of the foregoing examples of a polynucleotide that include a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein. In an example, the cell was contacted with any of the foregoing examples of a viral vector that include any of the foregoing examples of a polynucleotide that include a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein.

(13) In still another aspect, provided is an organism transfected with any of the foregoing examples

of a polynucleotide that include a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein. In an example, the organism was contacted with any of the foregoing examples of a viral vector.

(14) In another aspect, provided is a method. In an example, the method includes transfecting a cell with any of the foregoing examples of a polynucleotide that include a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein. In another example, transfecting includes contacting the cell with any of the foregoing examples of a viral vector that include any of the foregoing examples of a polynucleotide that include a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein. In still another example includes transfecting an organism with any of the foregoing examples of a polynucleotide that include a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein. In yet another example, transfecting includes contacting the organism with any of the foregoing examples of a viral vector that include any of the foregoing examples of a polynucleotide that include a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein.

(15) In another example, the organism is a mammal. In still another example, the organism is a human.

(16) In an example of the method, the vestigial like protein 4 does not include an HF to AA substitution in a TDU domain of the vestigial like protein 4 and the transfecting includes increasing a ratio of a volume of brown adipose tissue to a volume of white adipose tissue in the organism. In still another example, the vestigial like protein 4 does not include an HF to AA substitution in a TDU domain of the vestigial like protein 4 and the transfecting includes increasing a volume of brown adipose tissue in the organism, decreasing the volume of white adipose tissue in the organism, or both. In yet another example, the vestigial like protein 4 does not comprise an HF to AA substitution in a TDU domain and the transfecting includes reducing a ratio of a volume of adipose tissue to a volume of non-adipose tissue in the organism.

(17) In a further example, the vestigial like protein 4 does not include an HF to AA substitution in a TDU domain, and the organism is obese or is at risk of developing obesity. In still a further example, the vestigial like protein 4 does not include an HF to AA substitution in a TDU domain, and the transfecting includes preventing obesity in the organism. In yet another example, the vestigial like protein 4 does not include an HF to AA substitution in a TDU domain, and the transfecting includes treating obesity in the organism. In another example, the vestigial like protein 4 does not include an HF to AA substitution in a TDU domain, and the transfecting includes reducing obesity in the organism.

(18) In an example of the method, the vestigial like protein 4 includes an HF to AA substitution in each of two TDU domains, wherein the transfecting includes reducing a volume of adipose tissue of the organism. In another example, the vestigial like protein 4 includes an HF to AA substitution in each of two TDU domains, and the transfecting includes reducing a volume of brown adipose tissue of the organism. In still another example, the vestigial like protein 4 includes an HF to AA substitution in a TDU domain, and the organism is obese or is at risk of developing obesity. In yet another example, the vestigial like protein 4 includes an HF to AA substitution in a TDU domain, and the transfecting includes preventing obesity in the organism. In a further example, the transfecting includes treating obesity in the organism. In still a further example, the vestigial like protein 4 includes an HF to AA substitution in a TDU domain, and the transfecting includes reducing obesity in the organism.

(19) In an example of the method, the vestigial like protein 4 includes an HF to AA substitution in each of two TDU domains, and the transfecting includes reducing fatty acid synthesis in the organism. In another example, the vestigial like protein 4 includes an HF to AA substitution in a TDU domain, and the organism has hepatic steatosis or is at risk for developing hepatic steatosis. In still another example, the vestigial like protein 4 includes an HF to AA substitution in each of two TDU domains, and the transfecting includes preventing hepatic steatosis in the organism. In

yet another example, the vestigial like protein 4 includes an HF to AA substitution in each of two TDU domains, and the transfecting includes treating hepatic steatosis in the organism. In a further example, the vestigial like protein 4 includes an HF to AA substitution in each of two TDU domains, and the transfecting includes reducing hepatic steatosis in the organism.

(20) In an example of the method, the vestigial like protein 4 includes an HF to AA substitution in each of two TDU domains, and the organism has diabetes or is at risk of developing diabetes. In another example, the vestigial like protein 4 includes an HF to AA substitution in each of two TDU domains, wherein the transfecting includes preventing diabetes in the organism. In still another example, the vestigial like protein 4 includes an HF to AA substitution in each of two TDU domains, wherein the transfecting includes treating diabetes in the organism.

---

## Description

### BRIEF DESCRIPTION OF THE DRAWINGS

(1) These and other features, aspects, and advantages of the present disclosure will become better understood when the following detailed description is read with reference to the accompanying drawings, wherein:

(2) FIG. 1 shows a schematic view of constructs in accordance with aspects of the present disclosure.

(3) FIG. 2 shows timing of vector administration and expression measurement in accordance with aspects of the present disclosure.

(4) FIG. 3 shows representative bioluminescence images of a dorsal view of mice administered a viral vector in accordance with aspects of the present disclosure.

(5) FIG. 4 shows representative bioluminescence images of a ventral view of mice administered a viral vector in accordance with aspects of the present disclosure.

(6) FIG. 5 shows bioluminescence signal origin following viral vector administration in accordance with aspects of the present disclosure.

(7) FIG. 6 shows immunofluorescence staining images of interscapular BAT following viral vector administration in accordance with aspects of the present disclosure.

(8) FIG. 7 shows immunofluorescence staining images of interscapular BAT and WAT following viral vector administration in accordance with aspects of the present disclosure.

(9) FIG. 8 shows a schematic view of a construct in accordance with aspects of the present disclosure.

(10) FIG. 9 shows timing of vector administration and BAT and WAT measurement in accordance with aspects of the present disclosure.

(11) FIG. 10 shows relative BAT and WAT expression following treatment with control viral vector in accordance with aspects of the present disclosure.

(12) FIG. 11 shows relative BAT and WAT expression following treatment with a viral vector including a UCP-1 cis-regulatory element and Vgll4 coding sequence in accordance with aspects of the present disclosure.

(13) FIG. 12 shows an effect of treatment with a viral vector including a UCP-1 cis-regulatory element and Vgll4 coding sequence on BAT volume in accordance with aspects of the present disclosure.

(14) FIG. 13 shows an effect of treatment with a viral vector including a UCP-1 cis-regulatory element and Vgll4 coding sequence on WAT volume in accordance with aspects of the present disclosure.

(15) FIG. 14 shows an effect of treatment with a viral vector including a UCP-1 cis-regulatory element and Vgll4 coding sequence on the ratio of WAT volume to BAT volume in accordance with aspects of the present disclosure.

(16) FIG. 15 shows bioluminescent expression of a reporter protein, luciferase, in 6-week old mice administered viral vectors including cis-regulatory elements in accordance with the present disclosure.

(17) FIG. 16 shows quantification of luciferase activity in brown adipose tissue (BAT).

(18) FIG. 17 shows quantification of luciferase activity in liver.

(19) FIG. 18 shows quantification of viral vector genome copies in BAT and liver as assessed by real-time PCR.

(20) FIG. 19 is an illustration of the Hippo/YAP signaling cascade and Vgll4's inhibitory role in YAP/TEAD interactions.

(21) FIG. 20 shows the mutations made to two TONDU (TDU\_1 and TDU\_2) domains of Vgll4 isoforms. Vgll4 isoforms A through F include two TDU domains, TDU\_1 and TDU\_2, with the indicated sequences (SEQ ID NO: 41 and SEQ ID NO: 42). The Vgll4-H1F4A mutants of Vgll4 isoforms disclosed herein include two alanine substitutions to four amino acids, two in TDU\_1 (a histidine to alanine and a phenylalanine to alanine) and two in TDU\_2 (a histidine to alanine and a phenylalanine to alanine). Vgll4-HF4A have the dual-substituted TDU domains SEQ ID NO: 43 and SEQ ID NO: 44 (instead of SEQ ID NO: 41 and SEQ ID NO: 42, respectively).

(22) FIG. 21 is an illustration showing that whereas Vgll4 disrupts a YAP/TEAD1 complex, Vgll4-HF4A mutants do not.

(23) FIG. 22 Shows a schematic illustration of generation of brown adipocyte specific Tead1 knockout mice.

(24) FIG. 23 is a western blot showing confirmation of depleted expression of TEAD1 in brown adipose tissue of the conditional TEAD1 knockout mice, with GADPH as a control.

(25) FIG. 24 shows whole mount view of interscapular brown adipose tissue (iBAT) collected from 1-month old male mice. Bar=5 mm.

(26) FIG. 25 shows the ration between iBAT and body weight ratio (\* P<0.05).

(27) FIG. 26 shows qRT-PCR measurement of various mRNA transcript levels in BAT, normalized to 36B4.

(28) FIG. 27 is a genomic view of TEAD1 binding site in the Fgf21 promoter region.

(29) FIG. 28 is an illustration of experimental design for injecting adult mice fed a high-fat diet with a viral vector in accordance with the present disclosure. GTT is glucose tolerance test and ITT is insulin tolerance test.

(30) FIG. 29 shows bioluminescence imaging mice 8 weeks after infusion with viral vectors in accordance with the present disclosure.

(31) FIG. 30 and FIG. 31 show total body weight measurements and accumulated body weight gain measurements of transfected mice, respectively.

(32) FIGS. 32A, 32B, AND 32C show effects for transfection with a viral vector carrying a BCE-Vgll4 polynucleotide transcript on a ratio of total adipose tissue to tibia length, a ratio of total lean mass to tibia length, and a ratio of fat mass to lean mass. In 32A and 32B, AAV.Luciferase control is on the right and AAV.Vgll4 is on the right.

(33) FIG. 33A shows an illustration of an experimental design demonstrating that pre-treatment of mice with AAV.BCE.VGLL4 mitigates body weight gain. AAV.BCE.Vgll4 was subcutaneously injected into the interscapular region of 8-weeks-old C57/BL6 mice. After 13 weeks high fat diet treatment, mice were tested for glucose tolerance (GTT). AAV.BCE.GFP was used as control.

(34) FIGS. 33B and 33C show total body weight and accumulated body weight gain, respectively. AAV.GFP is the upper tracing and AAV.Vgll4.GFP is the lower.

(35) FIG. 33D shows fgf21 mRNA levels in BAT following transfection with a construct driving Vgll4 with a Ucp1 cis regulatory element in accordance with aspects of the present disclosure.

(36) FIGS. 34A and 34B show immunofluorescence images of interscapular brown adiposities (MCT1 was used to label the cell borders) and Vgll4 expression, respectively, of 8-week-old C57/BL6 mice 10 days after AAV.BCE.Vgll4 or AAV.BCE.GFP was subcutaneously injected into

the interscapular region.

(37) FIG. 34C AND 34D show real-time PCR measurements of various mRNA transcripts in brown adipose tissue. Control (AAV.BCE.GFP) is on the right and AAV.BCE.Vgll4-HF4A is on the right.

(38) FIG. 35A shows an illustration of an experimental design demonstrating that pre-treatment with an AAV.BCE.VGLL4-HF4A mitigates body weight gain. AAV.BCE.Vgll4-HF4A was subcutaneously injected into the interscapular region of 8-weeks-old C57/BL6 mice. After 12 weeks high fat diet treatment, mice were tested for glucose (GTT) and insulin tolerance (ITT). AAV.BCE.GFP was used as control.

(39) FIGS. 35B and 35C show total body weight and accumulated body weight gain, respectively. FIG. 35D shows serum glucose levels following glucose challenge in a glucose tolerance test. Upper traces are control and lower traces are AAV.BCE.Vgll4-HF4A.

(40) FIGS. 36A, 36B, 36C, 36D, AND 36E are graphs showing a ratio of brown adipose tissue weight to body weight, Vgll4 mRNA expression in BAT, Ucp1 mRNA expression in BAT, mitochondrial gene mRNA levels in BAT, and fatty acid synthesis gene mRNA expression in BAT. Student t test, \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ . Control (AAV.BCE.GFP) is on the right and AAV.BCE.Vgll4-HF4A is on the left.

(41) FIG. 37A shows that pre-treatment with AAV.BCE.Vgll4-HF4A reduces ratio of liver weight to body weight. FIG. 37B shows liver Vgll4 mRNA expression level. FIGS. 37C and 37D are photomicrographs showing HE staining and oil red staining, respectively, of liver sections (bar=100  $\mu\text{m}$ ). FIG. 37E shows mRNA levels of expression of fatty acid synthesis genes in liver by quantitative real-time PCR. A, B, E, Student t test, \*,  $P < 0.05$ ; \*\*  $P < 0.01$ . Control (AAV.BCE.GFP) is on the right and AAV.BCE.Vgll4-HF4A is on the right.

#### DETAILED DESCRIPTION

(42) This disclosure relates to a construct including a cis-regulatory element upstream of a coding sequence for a vestigial like 4 peptide (Vgll4). In an example, a cis-regulatory element may promote expression of a Vgll4 peptide in BAT cells. In an example, a cis-regulatory element may also promote expression of a Vgll4 peptide in liver cells. It may further specifically or enrichingly drive expression in BAT cells relative to expression driven in many or most other cells, when cells are transfected with the construct. In an example, it may further specifically or enrichingly drive expression in BAT and liver cells relative to expression driven in many or most other cells, when cells are transfected with the construct. Also disclosed is a viral vector including the construct, wherein the viral vector enables, permits, or promotes transfection of cells with the construct. In some examples, the Vgll4 peptide may include amino acid substitutions. For example, Vgll4 peptides include two TONDU (or TDU) domains, referred to herein as TDU\_1 and TDU\_2. Each TDU domain includes an HF dipeptide sequence. In an example, one or both HF TDU dipeptides may include amino acid substitutions, replacing HF with a dipeptide of aliphatic amino acids, such as AA.

(43) In an example, also disclosed is causing an increase in BAT, a decrease in WAT, an increase in a ratio of BAT volume to WAT volume, or any two of the foregoing, by contacting an organism with the construct, such as by transfecting cells of an organism with the construct. In an example, also disclosed is reducing a volume of adipose tissue of the organism by contacting an organism with the construct, such as by transfecting cells of an organism with the construct. In an example, also disclosed is reducing a mass ratio BAT to body weight of an organism by contacting an organism with the construct, such as by transfecting cells of an organism with the construct. In an example, also disclosed is reducing a liver volume, liver weight, intrahepatic fat content, or any combination of two or more of the foregoing, of an organism by contacting an organism with the construct, such as by transfecting cells of an organism with the construct.

(44) In an example, also disclosed is reducing or minimizing blood glucose levels or a rise in glucose levels in an organism by contacting an organism with the construct, such as by transfecting

cells of an organism with the construct. In an example, also disclosed is increasing expression of mitochondrial genes, such as mitochondrial genes involved in mitochondrial respiration, in an organism by contacting an organism with the construct, such as by transfecting cells of an organism with the construct. In an example, also disclosed is decreasing expression of genes that promote lipogenesis, in an organism by contacting an organism with the construct, such as by transfecting cells of an organism with the construct.

(45) In an example, a viral vector including the construct is used to transfect cells of an organism with the construct. A viral vector may be an adeno-associated viral vector or another viral vector known to be able to transfect cells. The organism may be a mammal, such as a rodent or human or any other mammal.

(46) Vgll4 is a transcription co-factor known to interact with cellular signaling molecules and transcription factors to influence cell survival and cell function. Vgll4 is particularly known for promoting cellular death by inhibiting YAP-TEAD1 complex. Several isoforms of Vgll4 have been identified, arising from splice variants to the Vgll4 gene. These include Vgll4A, Vgll4B, Vgll4C, Vgll4D, Vgll4E, and Vgll4F. Amino acid sequences of these Vgll4 proteins (referred to collectively here as Vgll4), and examples of polynucleotides encoding them, are given in Table II. Vgll4 has been linked with an anticancer effect in several types of cancer, where lower levels of Vgll4 correlate or correspond with or cause increased tumor cell survival and higher levels of Vgll4 correlate or correspond with or cause an anti-tumor effect including decreased metastatic processes and decreased tumor cell survival or proliferation. See Deng, Vgll4 is a transcriptional cofactor acting as a novel tumor suppressor via interacting with TEADs, *Am J Cancer Res* (2018), 8(6):932-943. In this respect, Vgll4 differs from other member of the vestigial like (Vgll) family (Vgll1, Vgll2, and Vgll3) of transcription co-factors, which are not known to have tumor-suppressive functions. Vgll family members other than Vgll4 are not generally understood to share functional commonalities with Vgll4.

(47) In view of the well-established role of increased Vgll4 expression in promoting cellular death processes or inhibiting cell survival, an increase in BAT volume as disclosed herein surprisingly results from Vgll4 expression influenced by a BAT-cell specific cis-regulatory element. In another example, and without being limited to any particular mechanism of action, where a Vgll4 protein includes HF to AA substitutions in both TDU domains, a reduced BAT volume, reduced intrahepatic fat accumulation, or both, may result from Vgll4 activity that does not include Vgll4 integration with a TEAD protein. In another example, and without being limited to any particular mechanism of action, where a Vgll4 protein includes HF to AA substitutions in both TDU domains, a reduced BAT volume, reduced intrahepatic fat accumulation, or both, may result from increased expression of mitochondrial genes involved in mitochondrial respiration, decreased expression of genes involved in lipogenesis, or both.

(48) For driving expression under control of a cis-regulatory element, cis-regulatory elements of uncoupling protein 1 (Ucp1) may be placed adjacent to a coding sequence for a Vgll4. By cis-regulatory element, what is meant is a nucleotide sequence that regulates the transcription of neighboring gene or coding sequences. Conventionally, Ucp1 is considered to be expressed specifically in BAT cells. Thus, such a cis-regulatory element may drive expression mostly, or predominantly, or in some cases exclusively, in BAT cells. Surprisingly, however, as disclosed herein, such a cis-regulatory element may drive expression in liver cells in addition to expression in BAT cells. In an example, such a cis-regulatory element may drive expression only in BAT and liver cells.

(49) A cis-regulatory element may include a promotor, an enhancer, or both. In some cases, a sequence for a cis-regulatory element may be located within fewer than 10 nucleotides from a transcription start site, fewer than 20 nucleotides from a transcription start site, fewer than 30 nucleotides from a transcription start site, fewer than 40 nucleotides from a transcription start site, fewer than 50 nucleotides from a transcription start site, fewer than 60 nucleotides from a

transcription start site, fewer than 70 nucleotides from a transcription start site, fewer than 80 nucleotides from a transcription start site, fewer than 90 nucleotides from a transcription start site, fewer than 100 nucleotides from a transcription start site, fewer than 125 nucleotides from a transcription start site, fewer than 150 nucleotides from a transcription start site, fewer than 175 nucleotides from a transcription start site, fewer than 200 nucleotides from a transcription start site, fewer than 225 nucleotides from a transcription start site, fewer than 250 nucleotides from a transcription start site, fewer than 275 nucleotides from a transcription start site, fewer than 300 nucleotides from a transcription start site, fewer than 325 nucleotides from a transcription start site, fewer than 35 nucleotides from a transcription start site, fewer than 375 nucleotides from a transcription start site, fewer than 400 nucleotides from a transcription start site, fewer than 425 nucleotides from a transcription start site, fewer than 450 nucleotides from a transcription start site, fewer than 475 nucleotides from a transcription start site, fewer than 500 nucleotides from a transcription start site, or between 500 and 1,000 nucleotides from a transcription start site

(50) A promoter is a nucleotide sequence to which RNA polymerizing enzymes bind for initiation of transcription of a downstream gene sequence. Many genes that show tissue- or cell-type specific expression including a promoter upstream of the DNA sequence that codes for the RNA that is particularly active in cells where the gene is expressed. A promoter may be more active in some cells than other, such as being active only in specific cell- or tissue-types, or highly active in certain cell- or tissue-types relative to others. Promoters include a sequence where transcription is initiated. Eukaryotic promoters may and typically do include features such as a TATA box, a transcription factor IIB recognition site, and a core promoter sequence (or an initiator). Transcription factors bind and RNA polymerase bind to a promoter for transcription initiation.

(51) Also included in a cis-regulatory element may be one or more enhancer sequence. An enhancer is part of a cis-regulatory element that enhances transcription initiated in or by the promoter. An enhancer may serve to promote an initiation of transcription at a promoter, for example, such as through binding of additional transcription factors to the enhancer that facilitate or enhance recruitment of other factors and transcriptional machinery to the promoter. As with promoters, many genes have enhancers that are involved in cell- or tissue-specific or cell- or tissue-enhanced expression.

(52) Ucp1 is a mitochondrial protein expressed specifically in BAT cells. The Ucp1 gene includes a cis regulatory element in which enhancer and promoter elements have been identified and characterized. Such cis-regulatory elements are responsible for promoting expression of neighboring gene sequences in BAT cells and not other tissue or cell types. Sequences that may be included in a cis regulatory element in accordance with the present disclosure as based on cis regulatory elements of Ucp1 genes are shown in Table I.

(53) TABLE-US-00001 TABLE I Cis Regulatory Element Sequences SEQ ID NO Identity  
Sequence 1 Mouse GCATGCCAATTTATAGTGCCGTCACCTAACAGTACTGATACTTTAA Ucp1  
CATGCTAAGTTTAAAGTGTGTGCTATATTAATTGTAAGATTGGTG enhancer  
AAGAGAGGTGTTATCAGATGGAAGCTGCACATTTCTGGATTAATG  
TGGTTAAATGTATCTTCTCCTGTGATTACTGTCTTTATTTCTTCTTT  
TAAAATATTGTCATTTGGACATCTATCTGTATAGCTACGCCCTGAC  
ACGTCCTCCTGGAGACAGATAAGAAGTTACGACGGGAGGAGCAG  
ATGGAGGCAAAGCGCTGTGATGCTTTTGTGGTTTGAGTGCACACA  
TTTGTTTCAGTGATTCTGTGAAATGAGTGAGCAAATGGTGACCGGG  
TGCCCTGTAAATGGTGTCTACATCTTAAGAGAAGAACACGGACA  
CTAGGTAAGTGAAGCTTGCTGTCACTCCTCTACAGCGTCACAGAG  
GGTCAGTCACCCTTGACCACACTGAACTAGTCGTCACCTTTCCACT  
CTTCCTGCCAGAAGAGCAGAAATCAGACTCTCTGGGGATATCAGC  
CTCACCCCTACTGCTCTCTCCATTATGAGGCAAACCTTTCTTTCACT  
TCCCAGAGGCTCTGGGGGCAGCAAGGTCAACCCTTTCCTCAGACT CTAG 2 Mouse

TCTCGGAGGAGGAGATCATGATCATCGCGCTTATTCAAGGGAACCCAGCCCCT Ucp1  
 GCTCTGCGCCCTGGTCCAAGGCTGTTGAAGAGTGACAAAAGGCAC promoter  
 CACGCTGCGGGGACGCGGGTGAAGCCCCCTCTGTGTGTCCTCTGGG  
 CATAATCAGGAAGTGGTGCCAAATCAGAGGTGATGTGGCCAGGG  
 CTTTGGGAGTGACGCGCGGCTGGGAGGCTTGCGCACCCAAGGCA  
 CGCCCCTGCCAAGTCCCAGTCCCTCCTCCGGCAAGGGGGCTATATA  
 GATCTCCCAGGTCAGGGCGCAG 3 Mouse  
 GCATGCCAATTTATAGTGCCGTCCTAACAGTACTGATACTTTAA Ucp1  
 CATGCTAAGTTTAAAGTGTGTGCTATATTAATTGTAAGATTGGTG enhancer-  
 AAGAGAGGTGTTATCAGATGGAAGCTGCACATTTCTGGATTAATG promoter  
 TGGTTAAATGTATCTTCTCCTGTGATTACTGTCTTTATTTCTTCTTT  
 TAAAATATTGTCATTTGGACATCTATCTGTATAGCTACGCCCTGAC  
 ACGTCCTCCTGGAGACAGATAAGAAGTTACGACGGGAGGAGCAG  
 ATGGAGGCAAAGCGCTGTGATGCTTTTGTGGTTTGAGTGCACACA  
 TTTGTTTCAAGTATTCTGTGAAATGAGTGAGCAAATGGTGACCGGG  
 TGCCCTGTAAATGGTGTCTACATCTTAAGAGAAGAACACGGACA  
 CTAGGTAAGTGAAGCTTGCTGTCACTCCTCTACAGCGTCACAGAG  
 GGTCAGTCACCCTTGACCACACTGAACTAGTCGTCACCTTTCCACT  
 CTTCTGCCAGAAGAGCAGAAATCAGACTCTCTGGGGATATCAGC  
 CTCACCCCTACTGCTCTCTCCATTATGAGGCCAACTTTCTTTCACT  
 TCCCAGAGGCTCTGGGGGGCAGCAAGGTCAACCCTTTCCTCAGACT  
 CTAGTCTCGGAGGAGATCAGATCGCGCTTATTCAAGGGAACCAGC  
 CCCTGCTCTGCGCCCTGGTCCAAGGCTGTTGAAGAGTGACAAAAG  
 GCACCACGCTGCGGGGACGCGGGTGAAGCCCCTCTGTGTGTCCTC  
 TGGGCATAATCAGGAAGTGGTGCCAAATCAGAGGTGATGTGGCC  
 AGGGCTTTGGGAGTGACGCGCGGCTGGGAGGCTTGCGCACCCAA  
 GGCACGCCCCTGCCAAGTCCCAGTCCCTCCTCCGGCAAGGGGGCTA  
 TATAGATCTCCCAGGTCAGGGCGCAG 4 Rat  
 GACGTCACAGTGGGTCAGTCACCCTTGATCACACTGCACCAGTCT adipose-  
 TCACCTTTCCACGCTTCCTGCCAGAGCATGAATCAGGCTCTCTGG specific  
 GGATACCGGCCTCACCCCTACTGAGGCCAACTTTCTCCCACTTCTC UCP1  
 AGAGGCTCTGAGGGCAGCAAGGTGAGCCCTTTCTTTGGAATCTAG enhancer  
 AACCCTCCCTGTCTTGAGCTGACATCACAGGGCAGGCAGATGCA  
 GCAGGGAAGGGCCTGGGACTGGGACGTTTCATCCTACAAGAAAGC  
 TGTGGAACTTTTTCAAGCAACATCTCA 5 Rat basal  
 GAAATCAGATCGCACTTATTCAAAGGAGCCAGGCCCTGCTCTGCG UCP1  
 CCCTGGTGGAGGCTCCTCATGTGAAGAGTGACAAAAGGCACCAT promoter  
 GTTGTGGATACGGGGCGAAGCCCCTCCGGTGTGTCTCTCCAGGCAT  
 CATCAGGAAGTGTGCCAAAGCAGAGGTGCTGGCCAGGGCTTTG  
 GGAGTGACGCGCGTCTGGGAGGCTTGTGCGCCCAGGGCACGCCC  
 CTGCCGATTCCCAGTCCAGGCTTTGGGGGACCTGGGCGGGCTCT  
 GCCCCTCCTCCAGCAATCGGGCTATAAAGCTCTTCCAAGTCAGGG  
 CGCAGAAGTGCCGGGCGATCCGGGCTTAAAGAGCGAGAGGAAGG  
 GACGCTCACCTTTGAGCTCCTCCACAAATAGCCCTGGTGGCTGCC  
 ACAGAAGTTTGAAGTTGAGAGTTCGG 6 Rat UCP1  
 GACGTCACAGTGGGTCAGTCACCCTTGATCACACTGCACCAGTCT enhancer  
 TCACCTTTCCACGCTTCCTGCCAGAGCATGAATCAGGCTCTCTGG with rat  
 GGATACCGGCCTCACCCCTACTGAGGCCAACTTTCTCCCACTTCTC basal



AGAGGCTCTGACCTGACCGCCCTTTCCTTTGGAATCGC UCP1  
 AACCACTCCCTGTCTTGAGCTGACATCACAGGGCAGGCAGATGCA promoter  
 GCAGGGAAGGGCCTGGGACTGGGACGTTTCATCCTACAAGAAAGC  
 TGTGGAACCTTTTCAGCAACATCTCAGAAATCAGATCGCACTTATT  
 CAAAGGAGCCAGGCCCTGCTCTGCGCCCTGGTGGAGGCTCCTCAT  
 GTGAAGAGTGACAAAAGGCACCATGTTGTGGATACGGGGCGAAG  
 CCCCTCCGGTGTGTCTCCAGGCATCATCAGGAAGTAGTGCCAAA  
 GCAGAGGTGCTGGCCAGGGCTTTGGGAGTGACGCGCGTCTGGGA  
 GGCTTGTGCGCCCAGGGCACGCCCCTGCCGATTCCCCTAGCAGG  
 TCTTGGGGGACCTGGGGCCGGCTCTGCCCTCCTCCAGCAATCGGG  
 CTATAAAGCTCTTCCAAGTCAGGGCGCAGAAGTGCCGGGGCGATCC  
 GGGCTTAAAGAGCGAGAGGAAGGGACGCTCACCTTTGAGCTCCT  
 CCACAAATAGCCCTGGTGGCTGCCACAGAAGTTCGAAGTTGAGA GTTCGG 7 Human  
 TGATCAAGTGCATTTGTTAATGTGTTCTACATTTTCAAAAAGGAA Ucp1  
 AGGAGAATTTGTTACATTCAGAACTTGCTGCCACTCCTTTGCTACG enhancer  
 TCATAAAGGGTCAGTTGCCCTTGCTCATACTGACCTATTCTTTACC  
 TCTCTGCTTCTTCTTTGTGCCAGAAGAGTAGAAATCTGACCCTTTG  
 GGGATAACCACCCTCTCCCCTACTGCTCTCTCCAACCTGAGGCAAA  
 CTTTCTCCTACTTCCCAGAGCCTGTCAGAAGTGGTGAAGCCAGCC  
 TGCTCCTTGGAATCCAGAACTACTTTCAGAATCTTGAACCTTCTGTG  
 ACCTCTCAGGGTCCC 8 Human  
 ACCGCCGCGGTGCGCCCTCCCTCCGACGTGCGGTGTGCGGGGGCGC Ucp1  
 AGACAACCAGCGGCCCGGCCAGGGCTTTCGGGGAGCGAAGCAGG promoter  
 GCTCCCGAGGCACCGAGCGAGAATGGGAATGGGAGGGACCCGGT  
 GCTCCCGGACACGCCCCCGGCAGGTCCCACGCCCCGGGTCTTCTGA  
 GACCTCGCGCGGCCAGCCCCGGGAGCGGCCAGCTATATAAGTCC  
 CAGCGGAAGACCGGAACGCAGAGGGTCTGCTGGCGCGAGGGTG  
 GGTAGGAGGGGACGCGGGGACT 9 Human  
 TGATCAAGTGCATTTGTTAATGTGTTCTACATTTTCAAAAAGGAA Ucp1  
 AGGAGAATTTGTTACATTCAGAACTTGCTGCCACTCCTTTGCTACG enhancer-  
 TCATAAAGGGTCAGTTGCCCTTGCTCATACTGACCTATTCTTTACC promoter  
 TCTCTGCTTCTTCTTTGTGCCAGAAGAGTAGAAATCTGACCCTTTG  
 GGGATAACCACCCTCTCCCCTACTGCTCTCTCCAACCTGAGGCAAA  
 CTTTCTCCTACTTCCCAGAGCCTGTCAGAAGTGGTGAAGCCAGCC  
 TGCTCCTTGGAATCCAGAACTACTTTCAGAATCTTGAACCTTCTGTG  
 ACCTCTCAGGGTCCCACCGCCGCGGTGCGCCCTCCCTCCGACGTG  
 CGGTGTGCGGGGCGCAGACAACCAGCGGCCGGGCCAGGGCTTTC  
 GGGGAGCGAAGCAGGGCTCCCGAGGCACCGAGCGAGAATGGGA  
 ATGGGAGGGACCCGGTGCTCCCGGACACGCCCCCGGCAGGTCCC  
 ACGCCCCGGGTCTTCTGAGACCTCGCGCGGCCAGCCCCGGGAGCGG  
 CCCAGCTATATAAGTCCCAGCGGAAGACCGGAACGCAGAGGGTC  
 CTGCTGGCGCGAGGGTGGGTAGGAGGGGACGCGGGGACT

(54) Examples of Ucp1 promoters include those of SEQ ID NO: 2, SEQ ID NO: 5, and SEQ ID NO: 8 (from mouse, rat, and human Ucp1 genes, respectively). Examples of Ucp1 enhancers include those of SEQ ID NO: 1, SEQ ID NO: 4, and SEQ ID NO: 7 (from mouse, rat, and human Ucp1 genes, respectively). In an example, presence of such a Ucp1 enhancer or Ucp1 promoter, or both, or of other Ucp1 enhancer or promoter elements, or both, in the cis-regulatory element of a gene may drive transcription and expression of such gene only in BAT, or only at high levels in BAT, or only at detectable levels in BAT, or at substantially higher levels in BAT compared to other cell types. In another example, presence of such a Ucp1 enhancer or Ucp1 promoter, or both, or of

other Ucp1 enhancer or promotor elements, or both, in the cis-regulatory element of a gene may also drive transcription and expression of such gene in liver cells. In some examples, a cis-regulatory element may include multiple Ucp1 enhancer elements, such as more than one of SEQ ID NO: 2, SEQ ID NO: 5, and SEQ ID NO: 8, or combination or combinations thereof.

(55) A Ucp1 cis-regulatory element may include a sequence of SEQ ID NO: 3, SEQ ID NO: 6, or SEQ ID NO: 9. Or, it may include a Ucp1 promotor without a Ucp1 enhancer. A Ucp1 cis-regulatory element may also include combinations of a Ucp1 enhancer and a Ucp1 promotor other than the aforementioned examples, such as any one or more of enhancer SEQ ID NO: 1, SEQ ID NO: 4, and SEQ ID NO: 7, together with any one of promotor SEQ ID NO: 2, SEQ ID NO: 5, and SEQ ID NO: 8. All possible combinations and permutations of the foregoing are explicitly contemplated herein and explicitly included as examples of the present disclosure.

(56) A cis-regulatory element including a rat Ucp1 enhancer of SEQ ID NO: 4 and a rat Ucp1 promotor of SEQ ID NO: 5 has previously been shown to drive expression of a neighboring gene in a BAT-specific manner. US Patent Application Publication No. 2016/0319303A1. As disclosed herein, a cis-regulatory element including a mouse Ucp1 enhancer of SEQ ID NO: 1, a mouse Ucp1 promotor of SEQ ID NO: 2, or both (as in SEQ ID NO: 3) may also drive expression of a neighboring gene in a BAT-specific manner. Surprisingly, as further disclosed herein, a cis-regulatory element including a Ucp1 enhancer and a Ucp1 promotor may also induce expression in liver cells. Some examples may have a Ucp1 enhancer sequence, Ucp1 promoter sequence, or Ucp1 cis-regulatory element, with 90% or more, or 95% or more, or 97.5% or more sequence homology with any of the corresponding, foregoing examples.

(57) Amino acid sequences, and non-limiting examples of nucleotide sequences encoding such Vgll4 peptide sequences, are shown in Table II.

(58) TABLE-US-00002 TABLE II Vgll4 sequences SEQ ID Identity NO Sequence 10 Vgll4A

ATGCTATTTATGAAGATGGACCTGTTGAACTATCAGTACTTGGAC nucleotide

AAGATGAACAACAATATCGGCATTCTGTGCTACGAAGGCGAAGC  
TGCTCTCAGGGGAGAACCCAGAATACAGACCCTGCCGGTGGCCTC  
TGCCCTCAGCAGTCACCGCACCGGCCCTCCCCCAATCAGCCCCAG  
CAAGAGGAAGTTCAGCATGGAGCCAGGTGACGAGGACCTAGACT  
GTGACAACGACCACGTCTCCAAAATGAGTCGCATCTTCAACCCCC  
ATCTGAACAAGACTGCCAATGGAGACTGCCGCAGAGACCCCCGG  
GAGCGGAGCCGCAGCCCCATCGAGCGCGCTGTGGCCCCCACCAT  
GAGCCTGCACGGCAGCCACCTGTACACCTCCCTCCCCAGCCTTGG  
CCTGGAGCAGCCCCTCGCACTGACCAAGAACAGCCTGGACGCCA  
GCAGGCCAGCCGGCCTCTCGCCACACTGACCCCGGGGGAGCGG  
CAGCAGAACCGGCCCTCCGTGATCACCTGTGCCTCGGCTGGCGCC  
CGCAACTGCAACCTCTCGCACTGCCCCATCGCGCACAGCGGCTGT  
GCCGCGCCCGGGCCTGCCAGCTACCGGAGGCCACCGAGCGCTGC  
CACCACCTGTGACCCCGTGGTGGAGGAGCATTTCGCGAGGAGCCT  
GGGCAAGAATTACAAGGAGCCCGAGCCGGCACCCAACTCCGTGT  
CCATCACGGGCTCCGTGGACGACCACTTTGCCAAAGCTCTGGGTG  
ACACGTGGCTCCAGATCAAAGCGGCCAAGGACGGAGCATCCAGC  
AGCCCTGAGTCCGCCTCTCGCAGGGGGCCAGCCCGCCAGCCCCCTCT  
GCCCACATGGTCAGCCACAGTCACTCCCCCTCTGTGGTCTCC 11 Vgll4A

MLFMKMDLLNYQYLDKMNNNIGILCYEGEAALRGEPRITLPVASA amino acid

LSSHRTGPPPIPSKRKFSMEPGDEDLDCDNDHVSMSRIFNPHLNKT  
ANGDCRRDPRERSRSPIERAVAPTMSLHGSHLYTSLPSLGLEQPLALT  
KNSLDASRPAGLSPTLTPGERQQNRPSVITCASAGARNCNLSHCPIAH  
SGCAAPGPASYRRPPSAATTCDPVVEEHFRRSLGKNYKEPEPAPNSV  
SITGSVDDHFAKALGDTWLQIKAADGASSPESASRRGQPASPSAH MVSHSHSPSVVS 12

Vgll4B ATGGATGGCCATTGGATTGTTGTCACAGGGCAGCATCTCTTGGTG nucleotide

CATGCTGATGACGAAAAACGCGAAGCTGCTCTCAGGGGAGAACC  
CAGAATACAGACCCCTGCCGGTGGCCTCTGCCCTCAGCAGTCACCG  
CACCGGCCCTCCCCCAATCAGCCCCAGCAAGAGGAAGTTCAGCAT  
GGAGCCAGGTGACGAGGACCTAGACTGTGACAACGACCACGTCT  
CCAAAATGAGTCGCATCTTCAACCCCCATCTGAACAAGACTGCCA  
ATGGAGACTGCCGCAGAGACCCCCGGGAGCGGAGCCGCAGCCCC  
ATCGAGCGCGCTGTGGCCCCCACCATGAGCCTGCACGGCAGCCAC  
CTGTACACCTCCCTCCCCAGCCTTGGCCTGGAGCAGCCCCCTCGCA  
CTGACCAAGAACAGCCTGGACGCCAGCAGGCCAGCCGGCCTCTC  
GCCCACACTGACCCCCGGGGGAGCGGCAGCAGAACCGGGCCCTCCG  
TGATCACCTGTGCCTCGGCTGGCGCCCCGCAACTGCAACCTCTCGC  
ACTGCCCCATCGCGCACAGCGGCTGTGCCGCGCCCCGGGCCTGCCA  
GCTACCGGAGGCCACCGAGCGCTGCCACCACCTGTGACCCCGTGG  
TGGAGGAGCATTTCGCGCAGGAGCCTGGGCAAGAATTACAAGGAG  
CCCGAGCCGGCACCCAACCTCCGTGTCCATCACGGGCTCCGTGGAC  
GACCACTTTGCCAAAGCTCTGGGTGACACGTGGCTCCAGATCAAA  
GCGGCCAAGGACGGAGCATCCAGCAGCCCTGAGTCCGCCTCTCGC  
AGGGGCCAGCCCGCCAGCCCCCTCTGCCCACATGGTCAGCCACAGT  
CACTCCCCCTCTGTGGTCTCC 13 Vgll4B

METPLDVLSRAASLVHADDEKREAAALRGEPRITLPVASALSSHRTG peptide

PPISPSCRKFSMEPGDEDLDCDNDHVS KM SRIFNPHLNKTANGDCR  
RDPRERSRSPIERAVAPTMSLHGSHLYTSLPSLGLEQPLALTKNSLDA  
SRPAGLSPTLTPGERQQNRPSVITCASAGARNCNLSHCPIAHSGCAAP  
GPASYRRPPSAATTCDPVVEEHFRRSLGKNYKEPEPAPNSVSITGSVD

DHFAKALGDTWLQIKA AKDGASSSPESASRRGQPASPSAHMVSHSH SPSVVS 14 Vgll4C

ATGATTAAAGTGAGGAACAAGACTGCCAATGGAGACTGCCGCAG nucleotide

AGACCCCCGGGAGCGGAGCCGCAGCCCCATCGAGCGCGCTGTGG  
CCCCACCATGAGCCTGCACGGCAGCCACCTGTACACCTCCCTCC  
CCAGCCTTGGCCTGGAGCAGCCCCTCGCACTGACCAAGAACAGCC  
TGGACGCCAGCAGGCCAGCCGGCCTCTCGCCCACACTGACCCCGG  
GGGAGCGGCAGCAGAACCGGCCCTCCGTGATCACCTGTGCCTCGG  
CTGGCGCCCGCAACTGCAACCTCTCGCACTGCCCCATCGCGCACA  
GCGGCTGTGCCGCGCCCCGGGCCTGCCAGCTACCGGAGGCCACCG  
AGCGCTGCCACCACCTGTGACCCCGTGGTGGAGGAGCATTTCGCG  
AGGAGCCTGGGCAAGAATTACAAGGAGCCCGAGCCGGCACCCAA  
CTCCGTGTCCATCACGGGCTCCGTGGACGACCACTTTGCCAAAGC  
TCTGGGTGACACGTGGCTCCAGATCAAAGCGGCCAAGGACGGAG  
CATCCAGCAGCCCTGAGTCCGCCTCTCGCAGGGGCCAGCCCGCCA  
GCCCCTCTGCCCACATGGTCAGCCACAGTCACTCCCCCTCTGTGGT CTCC 15 Vgll4C

MIKVRNKTANGDCRRDPRERSRSPIERAVAPTMSLHGSHLYTSLPSL amino acid

GLEQPLALTKNSLDASRPAGLSPTLTPGERQQNRPSVITCASAGARN  
CNLSHCPIAHSGCAAPGPASYRRPPSAATTCDPVVEEHFRRSLGKNYK  
EPEPAPNSVSITGSVDDHFAKALGDTWLQIKA AKDGASSSPESASRR  
GQPASPSAHMVSHSHSPSVVS 16 Vgll4D

ATGAACAAGACTGCCAATGGAGACTGCCGCAGAGACCCCCGGGA nucleotide

GCGGAGCCGCAGCCCCATCGAGCGCGCTGTGGCCCCCACCATGA  
GCCTGCACGGCAGCCACCTGTACACCTCCCTCCCCAGCCTTGGCC  
TGGAGCAGCCCCTCGCACTGACCAAGAACAGCCTGGACGCCAGC  
AGGCCAGCCGGCCTCTCGCCCACACTGACCCCGGGGGAGCGGCA

MTENTHFDKIPESCALKSWRHPGLHHGEAALRGEPRIQTLPVASALS amino acid  
SHRTGPPPIPSKRKFSMEPGDEDLDCDNDHVSMSRIFNPHLNKTA  
NGDCRRDPRERSRSPIERAVAPTMSLHGSHLYTSLPSLGLEQPLALTK  
NSLDASRPAGLSPTLTPGERQQNRPSVITCASAGARNCNLSHCPIAHS  
GCAAPGPASYRRPPSAATTCDPVVEEHFRRSLGKNYKEPEPAPNSVSI  
TGSVDDHFAKALGDTWLQIKAAKDGASSSPESASRRGQPASPSAHM VSHSHSPSVVS 20  
Vgll4F ATGGAGCCAGGTGACGAGGACCTAGACTGTGACAACGACCACGT nucleotide  
CTCCAAAATGAGTCGCATCTTCAACCCCCATCTGAACAAGACTGC  
CAATGGAGACTGCCGCAGAGACCCCCGGGAGCGGAGCCGCAGCC  
CCATCGAGCGCGCTGTGGCCCCCACCATGAGCCTGCACGGCAGCC  
ACCTGTACACCTCCCTCCCCAGCCTTGGCCTGGAGCAGCCCCTCG  
CACTGACCAAGAACAGCCTGGACGCCAGCAGGCCAGCCGGCCTC  
TCGCCCACACTGACCCCGGGGGAGCGGCAGCAGAACCGGCCCTC  
CGTGATCACCTGTGCCTCGGCTGGCGCCCGCAACTGCAACCTCTC  
GCACTGCCCCATCGCGCACAGCGGCTGTGCCGCGCCCGGGCCTGC  
CAGCTACCGGAGGCCACCGAGCGCTGCCACCACCTGTGACCCCGT

GGTGGAGGAGCCGCGCACCCAACTCCGTGTCCATCACGGGCTCCGTGG  
AGCCCGAGCCGGCACCCAACTCCGTGTCCATCACGGGCTCCGTGG  
ACGACCACTTTGCCAAAGCTCTGGGTGACACGTGGCTCCAGATCA  
AAGCGGCCAAGGACGGAGCATCCAGCAGCCCTGAGTCCGCCTCT  
CGCAGGGGGCCAGCCCGCCAGCCCCCTCTGCCCACATGGTCAGCCAC  
AGTCACTCCCCCTCTGTGGTCTCC 21 Vgll4F

MEPGDEDLDCDNDHVSKMSRIFNPHLNKTANGDCRRDPRERSRSPIE amino acid  
RAVAPTMSLHGSHLYTSLPSLGLEQPLALTKNSLDASRPAGLSPTLTP  
GERQQNRPSVITCASAGARNCNLSHCPIAHSGCAAPGPASYRRPPSA  
ATTCDPVVEEHFRRSLGKNYKEPEPAPNSVSITGSVDDHFAKALGDT  
WLQIKAAKDGASSSPESASRRGQPASPSAHMVSHSHSPSVVS

(59) At least six isoforms (A-F) of Vgll4 have been identified, referred to herein as Vgll4A, Vgll4B, Vgll4C, Vgll4D, Vgll4E, and Vgll4F, having amino acid sequences SEQ ID NO 11, SEQ ID NO 13, SEQ ID NO 15, SEQ ID NO 17, SEQ ID NO 19, and SEQ ID NO 21, respectively. These six isoforms are collectively included in the term Vgll4 as used herein. Also included herein is any nucleotide sequence that encodes any of the foregoing Vgll4 isoforms, including, without limitation, SEQ ID NO 10, SEQ ID NO: 12, SEQ ID NO 14, SEQ ID NO 16, SEQ ID NO 18, and SEQ ID NO: 20, including one or more codon substitution to any of the foregoing nucleotide sequences that nevertheless still encodes a Vgll4 (e.g., A-F), owing to codon degeneracy. A construct as disclosed herein may include a nucleotide sequence encoding a Vgll4 peptide as disclosed herein with any cis-regulatory element as disclosed herein, including without limitation one or more Ucp1 enhancer and a Ucp1 promotor, including any variation thereof described above. (60) A Vgll4 protein may be of human Vgll4 (SEQ ID NO 11, SEQ ID NO 13, SEQ ID NO 15, SEQ ID NO 17, SEQ ID NO 19, or SEQ ID NO 21), or mouse or rat Vgll4, or a Vgll4 sequence having at least 90%, at least 95%, or at least 97.5% homology with any of the foregoing examples in Table II. In an example, A Vgll4 peptide may include one or more amino acid substitution (relative to the examples disclosed in Table II). In an example, a Vgll4 peptide may include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions (relative to the examples disclosed in Table II). In an example, a Vgll4 peptide may have from 1 to 3 amino acid substitutions, or 2 amino acid substitutions, or 1 amino acid substitutions (relative to the examples disclosed in Table II). In an example, any of the foregoing amino acid substitutions may be outside of a TDU\_1 and TDU\_2 domain of the Vgll4 peptide.

(61) In another example, a Vgll4 peptide may include two amino acid substitutions an a TDU domain, or two amino acid substitutions in each of two TDU domains. A TDU\_1 domain has the amino acid sequence SEQ ID NO: 41. A TDU\_2 domain has the amino acid sequence SEQ ID NO: 42. Each of SEQ ID NO 11, SEQ ID NO 13, SEQ ID NO 15, SEQ ID NO 17, SEQ ID NO 19, and SEQ ID NO 21 includes a TDU\_1 domain with amino acid sequence SEQ ID NO: 41 and a TDU\_2 domain with amino acid sequence SEQ ID NO: 42. In some examples, a TDU\_1 domain may have an HF dipeptide amino acid sequence substituted with an AA dipeptide amino acid sequence, to yield the TDU\_1 amino acid sequence SEQ ID NO: 43. In some examples, a TDU\_2 domain may have an HF dipeptide amino acid sequence substituted with an AA dipeptide amino acid sequence, to yield the TDU\_2 amino acid sequence SEQ ID NO: 44. A Vgll4 peptide may include a TDU\_1 domain having an amino acid sequence of SEQ ID NO: 43 instead of an amino acid sequence of SEQ ID NO: 41. A Vgll4 peptide may include a TDU\_2 domain having an amino acid sequence of SEQ ID NO: 44 instead of an amino acid sequence of SEQ ID NO: 42. A Vgll peptide may include a TDU\_1 domain having an amino acid sequence of SEQ ID NO: 43 instead of an amino acid sequence of SEQ ID NO: 41 and include a TDU\_2 domain having an amino acid sequence of SEQ ID NO: 44 instead of an amino acid sequence of SEQ ID NO: 42. A Vgll4 peptide (e.g., Vgll4A, Vgll4B, Vgll4C, Vgll4D, Vgll4E, or Vgll4F) having TDU domains with amino acid sequences SEQ ID NO: 43 and SEQ ID NO: 44 instead of SEQ ID NO: 41 and SEQ ID NO: 42 is referred to

herein as a Vgll4-HF4A peptide.

(62) At least six isoforms (A-F) of Vgll4-HF4A are disclosed herein, referred to herein as Vgll4A-HF4A, Vgll4B-HF4A, Vgll4C-HF4A, Vgll4D-HF4A, Vgll4E-HF4A, and Vgll4F-HF4A. Amino acid sequences, and non-limiting examples of nucleotide sequences encoding such V 114-HF4A peptide sequences, are shown in Table III.

(63) TABLE-US-00003 TABLE III Vgll4-HF4A sequences SEQ ID NO Identity Sequence 22

Vgll4A- ATGCTATTTATGAAGATGGACCTGTTGAACTATCAGTACTTGGAC HF4A

AAGATGAACAACAATATCGGCATTCTGTGCTACGAAGGCGAAGC nucleotide

TGCTCTCAGGGGAGAACCCAGAATACAGACCCTGCCGGTGGCCTC

TGCCCTCAGCAGTCACCGCACCGGCCCTCCCCCAATCAGCCCCAG

CAAGAGGAAGTTCAGCATGGAGCCAGGTGACGAGGACCTAGACT

GTGACAACGACCACGTCTCCAAAATGAGTCGCATCTTCAACCCCC

ATCTGAACAAGACTGCCAATGGAGACTGCCGCAGAGACCCCCGG

GAGCGGAGCCGCAGCCCCATCGAGCGCGCTGTGGCCCCCACCAT

GAGCCTGCACGGCAGCCACCTGTACACCTCCCTCCCCAGCCTTGG

CCTGGAGCAGCCCCCTCGCACTGACCAAGAACAGCCTGGACGCCA

GCAGGCCAGCCGGCCTCTCGCCCACACTGACCCCGGGGGAGCGG

CAGCAGAACCGGCCCTCCGTGATCACCTGTGCCTCGGCTGGCGCC

CGCAACTGCAACCTCTCGCACTGCCCCATCGCGCACAGCGGCTGT

GCCGCGCCCCGGGCCTGCCAGCTACCGGAGGCCACCGAGCGCTGC

CACCACCTGTGACCCCGTGGTGGAGGAGGCAGCCCGCAGGAGCC

TGGGCAAGAATTACAAGGAGCCCGAGCCGGCACCCAACTCCGTG

TCCATCACGGGCTCCGTGGACGACGCAGCTGCCAAAGCTCTGGGT

GACACGTGGCTCCAGATCAAAGCGGCCAAGGACGGAGCATCCAG

CAGCCCTGAGTCCGCCTCTCGCAGGGGGCCAGCCCGCCAGCCCCCTC

TGCCCACATGGTCAGCCACAGTCACTCCCCCTCTGTGGTCTCC 23 Vgll4A-

MLFMKMDLLNYQYLDKMNNNIGILCYEGEAALRGEPRITLPVASA HF4A

LSSHRTGPPPISPSKRKFSMEPGDEDLDCDNDHVS KM SRIFNPHLNKT amino acid

ANGDCRRDPRERSRSPIERAVAPTMSLHGSHLYTSLPSLGLAQPLALT

KNSLDASRPAGLSPTLTTPGERQQNRPSVITCASAGARNCNLSHCPIAH

SGCAAPGPASYRRPPSAATTCDPVVEEAARRSLGKNYKEPEPAPNSV

SITGSVDDAAAKALGDTWLQIKA AKDGASSSPESASRRGQPASPSAH MVSHSHSPSVVS

24 Vgll4B- ATGGAGACGCCATTGGATGTTTTGTCCAGGGCAGCATCTCTGGTG HF4A

CATGCTGATGACGAAAAACGCGAAGCTGCTCTCAGGGGAGAACC nucleotide

CAGAATACAGACCCTGCCGGTGGCCTCTGCCCTCAGCAGTCACCG

CACCGGCCCTCCCCCAATCAGCCCCAGCAAGAGGAAGTTCAGCAT

GGAGCCAGGTGACGAGGACCTAGACTGTGACAACGACCACGTCT

CCAAAATGAGTCGCATCTTCAACCCCCATCTGAACAAGACTGCCA

ATGGAGACTGCCGCAGAGACCCCCGGGAGCGGAGCCGCAGCCCC

ATCGAGCGCGCTGTGGCCCCCACCATGAGCCTGCACGGCAGCCAC

CTGTACACCTCCCTCCCCAGCCTTGGCCTGGAGCAGCCCCCTCGCA

CTGACCAAGAACAGCCTGGACGCCAGCAGGCCAGCCGGCCTCTC

GCCCACACTGACCCCGGGGGAGCGGCAGCAGAACCGGCCCTCCG

TGATCACCTGTGCCTCGGCTGGCGCCCGCAACTGCAACCTCTCGC

ACTGCCCCATCGCGCACAGCGGCTGTGCCGCGCCCGGGCCTGCCA

GCTACCGGAGGCCACCGAGCGCTGCCACCACCTGTGACCCCGTGG

TGGAGGAGGCAGCCCGCAGGAGCCTGGGCAAGAATTACAAGGAG

CCCGAGCCGGCACCCAACTCCGTGTCCATCACGGGCTCCGTGGAC

GACGCAGCTGCCAAAGCTCTGGGTGACACGTGGCTCCAGATCAA

AGCGGCCAAGGACGGAGCATCCAGCAGCCCTGAGTCCGCCTCTC

GCAGGGCCGGCCGCTTGCCTGCCCACATGGTTCAGCCACA  
GTCACTCCCCCTCTGTGGTCTCC 25 Vgll4B-  
METPLDVL SRAASLVHADDEKREAA LRGEPRITLPVASALSSHRTG HF4A  
PPPISPSKRKFSMEPGDEDLDCDNDHVS KM SRIFNPHLNKTANGDCR peptide  
RDPRERSRSPIERAVAPTMSLHGSHLYTSLPSLGLEQPLALTKNSLDA  
SRPAGLSPTLTPGERQQNRPSVITCASAGARN CNLSHCPIAHSGCAAP  
GPASYRRPPSAATTCDPVVEEAARRSLGKNYKEPEPAPNSVSITGSVD  
DAAAKALGDTWLQIKA AKDGASSSPESASRRGQPASPSAHMVSHSH SPSVVS 26 Vgll4C-  
ATGATTAAAGTGAGGAACAAGACTGCCAATGGAGACTGCCGCAG HF4A  
AGACCCCCGGGAGCGGAGCCGCAGCCCCATCGAGCGCGCTGTGG nucleotide  
CCCCACCATGAGCCTGCACGGCAGCCACCTGTACACCTCCCTCC  
CCAGCCTTGGCCTGGAGCAGCCCCTCGCACTGACCAAGAACAGCC  
TGGACGCCAGCAGGCCAGCCGGCCTCTCGCCCACACTGACCCCGG  
GGGAGCGGCAGCAGAACCGGCCCTCCGTGATCACCTGTGCCTCGG  
CTGGCGCCCGCAACTGCAACCTCTCGCACTGCCCCATCGCGCACA  
GCGGCTGTGCCGCGCCCGGGCCTGCCAGCTACCGGAGGCCACCG  
AGCGCTGCCACCACCTGTGACCCCGTGGTGGAGGAGGCAGCCCG  
CAGGAGCCTGGGCAAGAATTACAAGGAGCCCGAGCCGGCACCCA  
ACTCCGTGTCCATCACGGGCTCCGTGGACGACGCAGCTGCCAAAG  
CTCTGGGTGACACGTGGCTCCAGATCAAAGCGGCCAAGGACGGA  
GCATCCAGCAGCCCTGAGTCCGCCTCTCGCAGGGGGCCAGCCCGCC  
AGCCCCTCTGCCCACATGGTCAGCCACAGTCACTCCCCCTCTGTG GTCTCC 27 Vgll4C-  
MIKVRNKTANGDCRRDPRERSRSPIERAVAPTMSLHGSHLYTSLPSL HF4A  
GLEQPLALTKNSLDASRPAGLSPTLTPGERQQNRPSVITCASAGARN amino acid  
CNLSHCPIAHSGCAAPGPASYRRPPSAATTCDPVVEEAARRSLGKNYK  
EPEPAPNSVSITGSVDDAAAKALGDTWLQIKA AKDGASSSPESASRR  
GQPASPSAHMVSHSHSPSVVS 28 Vgll4D-  
ATGAACAAGACTGCCAATGGAGACTGCCGCAGAGACCCCCGGGA HF4A  
GCGGAGCCGCAGCCCCATCGAGCGCGCTGTGGCCCCCACCATGA nucleotide  
GCCTGCACGGCAGCCACCTGTACACCTCCCTCCCCAGCCTTGGCC  
TGGAGCAGCCCCTCGCACTGACCAAGAACAGCCTGGACGCCAGC  
AGGCCAGCCGGCCTCTCGCCCACACTGACCCCGGGGGAGCGGCA  
GCAGAACCGGCCCTCCGTGATCACCTGTGCCTCGGCTGGCGCCCG  
CAACTGCAACCTCTCGCACTGCCCCATCGCGCACAGCGGCTGTGC  
CGCGCCCGGGCCTGCCAGCTACCGGAGGCCACCGAGCGCTGCCA  
CCACCTGTGACCCCGTGGTGGAGGAGGCAGCCCGCAGGAGCCTG  
GGCAAGAATTACAAGGAGCCCGAGCCGGCACCCA ACTCCGTGTC  
CATCACGGGCTCCGTGGACGACGCAGCTGCCAAAGCTCTGGGTGA  
CACGTGGCTCCAGATCAAAGCGGCCAAGGACGGAGCATCCAGCA  
GCCCTGAGTCCGCCTCTCGCAGGGGGCCAGCCCGCCAGCCCCTCTG  
CCCACATGGTCAGCCACAGTCACTCCCCCTCTGTGGTCTCC 29 Vgll4D-  
MNKTANGDCRRDPRERSRSPIERAVAPTMSLHGSHLYTSLPSLGLEQ HF4A  
PLALTKNSLDASRPAGLSPTLTPGERQQNRPSVITCASAGARN CNLSH amino acid  
CPIAHSGCAAPGPASYRRPPSAATTCDPVVEEAARRSLGKNYKEPEP  
APNSVSITGSVDDAAAKALGDTWLQIKA AKDGASSSPESASRRGQPA  
SPSAH MVSHSHSPSVVS 30 Vgll4E-  
ATGACTGAGAATACGCATTTTGACAAAATCCCTGAGTCCTGTGCA HF4A  
CTCAAAGTTGGAGACATCCAGGTCTGCACCATGGCGAAGCTGCT nucleotide  
CTCAGGGGAGAACCCAGAATACAGACCCTGCCGGTGGCCTCTGCC  
CTCAGCAGTCACCGCACCGGCCCTCCCCCAATCAGCCCCAGCAAG

AGGAAGTTGACGTGAGGACCTGAGACTGTGA  
CAACGACCACGTCTCCAAAATGAGTCGCATCTTCAACCCCCATCT  
GAACAAGACTGCCAATGGAGACTGCCGCAGAGACCCCCGGGAGC  
GGAGCCGCAGCCCCATCGAGCGCGCTGTGGCCCCCACCATGAGCC  
TGCACGGCAGCCACCTGTACACCTCCCTCCCCAGCCTTGGCCTGG  
AGCAGCCCCCTCGCACTGACCAAGAACAGCCTGGACGCCAGCAGG  
CCAGCCGGCCTCTCGCCCACACTGACCCCGGGGGAGCGGCAGCA  
GAACCGGGCCCTCCGTGATCACCTGTGCCTCGGCTGGCGCCCCGCAA  
CTGCAACCTCTCGCACTGCCCCATCGCGCACAGCGGCTGTGCCGC  
GCCCCGGGCCTGCCAGCTACCGGAGGCCACCGAGCGCTGCCACCA  
CCTGTGACCCCGTGGTGGAGGAGGCAGCCCGCAGGAGCCTGGGC  
AAGAATTACAAGGAGCCCGAGCCGGCACCCAACTCCGTGTCCATC  
ACGGGCTCCGTGGACGACGCAGCTGCCAAAGCTCTGGGTGACAC  
GTGGCTCCAGATCAAAGCGGCCAAGGACGGAGCATCCAGCAGCC  
CTGAGTCCGCCTCTCGCAGGGGGCCAGCCCGCCAGCCCCCTCTGCCC  
ACATGGTCAGCCACAGTCACTCCCCCTCTGTGGTCTCC 31 Vgll4E-  
MTENTHFDKIPESCALKSWRHPGLHHGEAALRGEPRITLPVASALS HF4A  
SHRTGPPPISPSKRKFSMEPGDEDLDCDNDHVSKMSRIFNPHLNKTA amino acid  
NGDCRRDPRERSRSPIERAVAPTMSLHGSHLYTSLPSLGLAQPLALTK  
NSLDASRPAGLSPTLTPGERQQNRPSVITCASAGARNCNLSHCPIAHS  
GCAAPGPASYRRPPSAATTCDPVVEEAARRSLGKNYKEPEPAPNSVS  
ITGSVDDAAAKALGDTWLQIKAADGASSSPESASRRGQPASPSAH MVSHSHSPSVVS 32  
Vgll4F- ATGGAGCCAGGTGACGAGGACCTAGACTGTGACAACGACCACGT HF4A  
CTCCAAAATGAGTCGCATCTTCAACCCCCATCTGAACAAGACTGC nucleotide  
CAATGGAGACTGCCGCAGAGACCCCCGGGAGCGGAGCCGCAGCC  
CCATCGAGCGCGCTGTGGCCCCCACCATGAGCCTGCACGGCAGCC  
ACCTGTACACCTCCCTCCCCAGCCTTGGCCTGGAGCAGCCCCCTCG  
CACTGACCAAGAACAGCCTGGACGCCAGCAGGCCAGCCGGCCTC  
TCGCCCACACTGACCCCGGGGGAGCGGCAGCAGAACCGGCCCTC  
CGTGATCACCTGTGCCTCGGCTGGCGCCCGCAACTGCAACCTCTC  
GCACTGCCCCATCGCGCACAGCGGCTGTGCCGCGCCCGGGCCTGC  
CAGCTACCGGAGGCCACCGAGCGCTGCCACCACCTGTGACCCCGT  
GGTGGAGGAGGCAGCCCGCAGGAGCCTGGGCAAGAATTACAAGG  
AGCCCGAGCCGGCACCCAACTCCGTGTCCATCACGGGCTCCGTGG  
ACGACGCAGCTGCCAAAGCTCTGGGTGACACGTGGCTCCAGATCA  
AAGCGGCCAAGGACGGAGCATCCAGCAGCCCTGAGTCCGCCTCT  
CGCAGGGGGCCAGCCCGCCAGCCCCCTCTGCCCACATGGTCAGCCAC  
AGTCACTCCCCCTCTGTGGTCTCC 33 Vgll4F-  
MEPGDEDLDCDNDHVSKMSRIFNPHLNKTANGDCRRDPRERSRSPIE HF4A  
RAVAPTMSLHGSHLYTSLPSLGLAQPLALTKNSLDASRPAGLSPTLTP amino acid  
GERQQNRPSVITCASAGARNCNLSHCPIAHSGCAAPGPASYRRPPSA  
ATTCDPVVEEAARRSLGKNYKEPEPAPNSVSITGSVDDAAAKALGDT  
WLQIKAADGASSSPESASRRGQPASPSAHMVSHSHSPSVVS

(64) As disclosed herein, a Vgll4-HF4A peptide may have an amino acid sequence of s SEQ ID NO 23, SEQ ID NO 25, SEQ ID NO 27, SEQ ID NO 29, SEQ ID NO 31, or SEQ ID NO 33. These six isoforms are collectively included in the term Vgll4-HF4A as used herein. Also included herein is any nucleotide sequence that encodes any of the foregoing Vgll4 isoforms, including, without limitation, SEQ ID NO 22, SEQ ID NO: 24, SEQ ID NO 26, SEQ ID NO 28, SEQ ID NO 30, and SEQ ID NO: 32, including one or more codon substitution to any of the foregoing nucleotide sequences that nevertheless still encodes a Vgll4-HF4A (e.g., A-F), owing to codon degeneracy. A



construct as disclosed herein may include a nucleotide sequence encoding a Vgll4-HF4A peptide as disclosed herein with any cis-regulatory element as disclosed herein, including without limitation one or more Ucp1 enhancer and a Ucp1 promotor, including any variation thereof described above. (65) A Vgll4-HF4A protein may be a human Vgll4, or mouse or rat Vgll4, bearing an HF to AA substitution in its TDU domains, or a Vgll4-HF4A sequence having at least 90%, at least 95%, or at least 97.5% homology with any of the foregoing examples in Table III. In an example, a Vgll4-HF4A peptide may include one or more amino acid substitution (relative to the examples disclosed in Table III) outside a TDU\_1 and TDU\_2 domain. In an example, a Vgll4-HF4A peptide may include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions (relative to sequences disclosed in Table III) outside a TDU\_1 and TDU\_2 domain. In an example, a Vgll4-HF4A peptide may have from 1 to 3 amino acid substitutions, or 2 amino acid substitutions, or 1 amino acid substitution (relative to sequences disclosed in Table III) outside a TDU\_1 and TDU\_2 domain.

(66) In some examples, an intron may be included between a cis-regulatory element and a gene encoding Vgll4. In some examples, an intron may enhance or promote transcription or promote stability of an RNA transcript. Other examples do not include an intron. Various intronic sequences are known by skilled artisans to be able to be included in recombinant constructs for promoting gene expression, any of which could be included in a construct as disclosed herein. In an example, an intron of SEQ ID NO: 34 (a chimeric intron of human b-globin and immunoglobulin heavy chain genes) may be included, or a sequence having at least 90%, at least 95%, or at least 97.5% sequence homology therewith.

(67) A summary of aspects of a construct including a cis regulatory element and a Vgll4-encoding nucleotide sequence, and a cis regulatory element and a Vgll4-HF4A-encoding nucleotide sequence, as disclosed herein are shown in Tables IV and V, respectively.

(68) TABLE-US-00004 TABLE IV Vgll4 constructs cis-Regulatory Elements Optional intron Vgll4 Enhancer sequences Promoter sequences SEQ ID NO: 34 Amino acid sequences: SEQ ID NO: 1 SEQ ID NO: 2 GTAAGTATCAAGG SEQ ID NO: 11 SEQ ID NO: 4 SEQ ID NO: 5 TTACAAGACAGGT SEQ ID NO: 13 SEQ ID NO: 7 SEQ ID NO: 8 TTAAGGAGACCAA SEQ ID NO: 15 TAGAAACTGGGCT SEQ ID NO: 17 TGTCGAGACAGAG SEQ ID NO: 19 AAGACTCTTGCGTT SEQ ID NO: 21 Enhancer-promoter sequences: TCTGATAGGCACCT Nucleotide sequences: SEQ ID NO: 3 ATTGGTCTTACTGA SEQ ID NO: 10 SEQ ID NO: 6 CATCCACTTTGCCT SEQ ID NO: 12 SEQ ID NO: 9 TTCTCTCCACAG SEQ ID NO: 14 SEQ ID NO: 16 SEQ ID NO: 18 SEQ ID NO: 20

(69) TABLE-US-00005 TABLE V Vgll4-HF4A constructs cis-Regulatory Elements Optional intron Vgll4-HF4A Enhancer sequences Promoter sequences SEQ ID NO: 34 Amino acid sequences: SEQ ID NO: 1 SEQ ID NO: 2 GTAAGTATCAAGG SEQ ID NO: 23 SEQ ID NO: 4 SEQ ID NO: 5 TTACAAGACAGGT SEQ ID NO: 25 SEQ ID NO: 7 SEQ ID NO: 8 TTAAGGAGACCAA SEQ ID NO: 27 TAGAAACTGGGCT SEQ ID NO: 29 TGTCGAGACAGAG SEQ ID NO: 31 AAGACTCTTGCGTT SEQ ID NO: 33 Enhancer-promoter sequences: TCTGATAGGCACCT Nucleotide sequences: SEQ ID NO: 3 ATTGGTCTTACTGA SEQ ID NO: 22 SEQ ID NO: 6 CATCCACTTTGCCT SEQ ID NO: 24 SEQ ID NO: 9 TTCTCTCCACAG SEQ ID NO: 26 SEQ ID NO: 28 SEQ ID NO: 30 SEQ ID NO: 32

(70) A construct as disclosed herein may include a cis regulatory element and a nucleotide sequence encoding a Vgll4 or Vgll4-HF4A peptide. A cis regulatory element may include, for example, any one or more of enhancer sequence SEQ ID NO: 1, SEQ ID NO: 4, and SEQ ID NO: 7, and any one of promoter sequence SEQ ID NO: 2, SEQ ID NO: 5, and SEQ ID NO: 8. All permutations of the foregoing are expressly contemplated and included in the present disclosure. In

an example, a cis-regulatory element may include 2, 3, or 4 enhancer sequences each independently selected from SEQ ID NO: 1, SEQ ID NO: 4, and SEQ ID NO: 7. Examples of cis regulatory elements include SEQ ID NO: 3, SEQ ID NO: 6, and SEQ ID NO: 9.

(71) A Vgll4 peptide encoded by a Vgll4 peptide-encoding nucleotide sequence of a construct may include, for example, any of SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, and SEQ ID NO: 21, or any variation thereof as further explained above. Examples include SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, and SEQ ID NO: 20. Vgll4-HF4A peptide encoded by a Vgll4-HF4A peptide-encoding nucleotide sequence of a construct may include, for example, any of SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, and SEQ ID NO: 31, or any variation thereof as further explained above. Examples include SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, and SEQ ID NO: 32. A construct may include any cis regulatory element as disclosed herein and any Vgll4- or Vgll4-HF4A-encoding nucleotide sequence as disclosed herein. Optionally, a construct may also include an intron between a cis regulatory element and a Vgll4- or Vgll4-HF4A-encoding nucleotide sequence. A non-limiting example of an optional intron is SEQ ID NO: 34. In other examples, nucleotides other than an intron or having an intronic nucleotide sequence other than SEQ ID NO: 34 may be included in a construct between a cis regulatory element and a Vgll4- or Vgll4-HF4A-encoding nucleotide sequence. An example of a Vgll4A construct is SEQ ID NO: 35 and an example of a Vgll4-HF4A construct is SEQ ID NO: 36.

(72) A cell may be transfected with a construct as disclosed above by various methods, such as chemical transfection, electroporation, impalefaction, gene gun transfection, or viral vector mediated gene transfer, or any other method known to skilled persons in the relevant field. In an example, a Vgll4 gene with associated Ucp1 cis-regulatory element is packaged in a viral vector for cellular transfection. Viral vector in this case refers to a viral-like particle that contains or includes a payload gene construct or cassette capable of attaching to a cell and delivering the payload into the cell. In some examples, a viral vector may be of a type wherein a payload, once introduced into a transfected cell, integrates into the cell's genomic DNA, though such genomic integration is not an essential feature of a viral vector as disclosed herein. Viral vector may also refer to a gene sequence including a gene construct or cassette structured for inclusion in a viral-like particle. Examples of viral vectors include retroviruses, lentiviruses, adenoviruses, and adeno-associated viruses (AAV). Several serotypes of AAV vectors are useful for cellular transfection, including any of serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11, or subtypes thereof. Sequences for such AAV serotypes are known and may be found in publicly accessible databases, as are methods of packaging a construct of interest in viral vector particles for cellular transfection and promotion of construct expression in transfected cells.

(73) An AAV vector includes sequences bounding a payload construct referred to as inverted terminal repeats (ITRs). ITR sequences are involved in transcription of AAV genome, encapsulation of payload in a vector particle, genome multiplication for particle generation, and integration into host genome. A cassette, construct, transgene, payload, etc., placed between ITRs of an AAV vector may promote production of an AAV vector and/or expression of transfected gene within cells. In an example, a Ucp1 cis-regulatory element neighboring a nucleotide sequence encoding a Vgll4 or Vgll4-HFA peptide may be placed between ITRs and used for generation of an AAV particle, wherein said particle may be contacted with cells of an organism to transfect them with such construct. An example includes an AAV9 serotype AAV containing such construct, though other serotypes may also be used.

(74) In some cases a reporter gene may be used or included in a construct to verify expression of a construct gene included in a vector or for testing tissue- or cell-type specific expression of a gene under control of a given cis-regulatory element. Numerous reporter genes are known and have been widely used in the relevant field. A non-limiting list of examples includes a green fluorescent

protein (for example, having an amino acid sequence of SEQ ID NO: 37, encoded for by a nucleotide sequence of SEQ ID NO: 38 or any other nucleotide sequence as may encode an amino acid sequence of SEQ ID NO: 37 according to principles codon degeneracy), a yellow fluorescent protein, a red fluorescent protein, a blue fluorescent protein, a luciferase protein, a beta-galactosidase protein, a glutathione S-transferase protein, a chloramphenicol acetyltransferase protein, and any combination of two or more of the foregoing. Other reporters may also be included. In other examples, no reporter is included. By detecting expression of a reporter protein, the ability of a given cis-regulatory element, or viral vector, to promote transfection and/or expression in various cell and tissue types can be evaluated. A reporter protein sequence may occur immediately before the N-terminal or immediately after the C-terminal amino acid of a Vgll4 or Vgll4-HF4A peptide as disclosed herein, or may be separated by one or more amino acids from the N- or C-terminal amino acid of a Vgll4 or Vgll4-HF4A peptide. A construct may include any nucleotide sequence for encoding any reporter protein. A non-limiting example of a Vgll4 construct including a sequence encoding a GFP-encoding reported protein is SEQ ID NO: 39. In another non-limiting example, SEQ ID NO: 39 may be modified to replace SEQ ID NO: 41 therein and SEQ ID NO: 42 therein with SEQ ID NO: 43 and SEQ ID NO: 44, respectively, to encode a Vgll4-HF4A and a GFP reporter protein.

(75) A viral vector or viral-like particle, such as an AAV vector, can be injected into an organism, such as subcutaneously, intramuscularly, intravenously, intraperitoneally, or by other methods for introduction of the vector into the organism for contact with cells thereof. A vector may contact various different cell and tissue types and transfect them. However, inclusion of a cell- or tissue-specific cis-regulatory element (enhancer, promoter, or both) may restrict expression of the transfected gene to a given cell or tissue type or types, wherein the construct is not transcribed or is otherwise dormant or at most barely or minimally expressed in other cell types. As explained above, a cis-regulatory element may include elements that are known or believed to drive expression in adipocytes, or fat cells, specifically, including in specific subtypes of fat cells, such as predominantly in BAT cells. However, it is not necessary that expression be limited absolutely to a given cell type, including only in BAT cells, even under control of a Ucp1 cis-regulatory element. For example, although Ucp1 expression is believed to be restricted to mature BAT cells, it is possible that other cell types may from time to time express a construct whose expression is influenced by a neighboring cis-regulatory element such as a Ucp1 enhancer, promoter, or both. Surprisingly, in some circumstances, as disclosed herein, a Ucp1 cis-regulatory element may include expression in liver cells in addition to BAT cells.

(76) In an example, contacting the cells of an organism with a nucleotide sequence including a Ucp1 cis-regulatory element and a coding sequence for a Vgll4 protein or variant may increase BAT volume, lower WAT volume, increase a ratio of BAT volume to WAT volume, or any combination of the foregoing, even if Vgll4 expression under control of the cis-regulatory element is not strictly limited to BAT cells containing the transgene. In another example, a construct may

(77) In another example, transfecting cells of an organism with a nucleotide sequence including a Ucp1 cis-regulatory element and a coding sequence for a Vgll4 protein or variant may reduce a volume of adipose tissue of the organism. In another example, transfecting cells of an organism with a nucleotide sequence including a Ucp1 cis-regulatory element and a coding sequence for a Vgll4 protein or variant may reduce a mass ratio BAT to body weight of the organism.

(78) In another example, disclosed herein is a method for prevention or treatment of obesity, by transfecting cells of an organism with any of the foregoing constructs disclosed herein including a cis-regulatory element and nucleotide sequence encoding a Vgll4 peptide or a Vgll4-HF4A peptide.

(79) In another example, transfecting cells of an organism with a nucleotide sequence including a Ucp1 cis-regulatory element and a coding sequence for a Vgll4 protein or variant may reduce a liver volume, liver weight, intrahepatic fat content, or any combination of two or more of the foregoing, of the organism. An intrahepatic fat content of at least 5% of liver weight is referred to

as hepatic steatosis. Obesity, or risk of developing obesity, such as genetic or life-style factors (e.g., high-calorie or high-fat diet, low exercise or caloric burn rate, sedentary lifestyle, etc.), are risk factors for developing elevated hepatic steatosis. Obesity may be defined as having a body mass index (BMI) of 30 or higher. An example of a risk factor for developing obesity may be having a BMI of from 25 to 29, which is considered being overweight. Prolonged hepatic steatosis is a risk factor for disorders including liver metabolic dysfunction, inflammation, and advanced forms of nonalcoholic fatty liver disease. Disclosed herein is a method for prevention or treatment of hepatic steatosis, by transfecting cells of an organism with any of the foregoing constructs disclosed herein including a cis-regulatory element and nucleotide sequence encoding a Vgll4 peptide or a Vgll4-HF4A peptide.

(80) In another example, transfecting cells of an organism with a nucleotide sequence including a Ucp1 cis-regulatory element and a coding sequence for a Vgll4 protein or variant may reduce or minimize blood glucose levels or a rise in glucose levels or duration of such rise in an organism. Obesity is a risk factor for diabetes, which includes pathological dysregulation of glucose levels, specifically pathological elevations in serum glucose levels or pathologically elevated duration of elevated serum glucose levels such as following calorie intake such as a meal. In an example, a rise in serum glucose may be measured following administration of a glucose challenge (i.e., consuming a glucose solution). Normally, a rise in serum glucose follows such a challenge, which rise then returns to baseline or near baseline. In individuals with diabetes, however, glucose may rise pathologically higher and/or for a pathologically longer duration than in individuals without diabetes. For individuals with diabetes or at risk for developing diabetes (e.g., family history, genetic or other biomarker-evincing predisposition, obesity, etc.), a treatment for preventing pathological rise in serum glucose levels, or a pathological extension of a rise in serum glucose levels, following a meal or a glucose challenge is advantageous. An example in accordance with the present disclosure includes reducing or minimizing blood glucose levels or a rise in glucose levels in an organism by contacting an organism with the construct, such as by transfecting cells of an organism with the construct. An example in accordance with the present disclosure includes preventing development of a pathologically high rise in blood glucose levels or a pathologically high duration of a rise in blood glucose levels in an organism with diabetes or at risk for developing diabetes by contacting an organism with the construct, such as by transfecting cells of the organism. The organism may be an obese person, or a person at risk of developing obesity, or a person diagnosed with diabetes, or a person at risk of developing diabetes. Accordingly, an example disclosed herein includes a method for prevention or treatment of diabetes, by transfecting cells of an organism with any of the foregoing constructs disclosed herein including a cis-regulatory element and nucleotide sequence encoding a Vgll4 peptide or a Vgll4-HF4A peptide.

(81) In an example, also disclosed is increasing expression of mitochondrial genes, such as mitochondrial genes involved in mitochondrial respiration, in an organism by contacting an organism with the construct, such as by transfecting cells of an organism with the construct. In an example, also disclosed is decreasing expression of genes that promote lipogenesis, in an organism by contacting an organism with the construct, such as by transfecting cells of an organism with the construct. Increasing mitochondrial genes that promote mitochondrial respiration, or decreasing expression of genes involved in lipogenesis, such as in BAT or liver cells of an organism transfected with a construct as disclosed herein (e.g., including a Ucp1 cis regulatory element and a nucleotide sequence encoding a Vgll4- or Vgll4-HFA-encoding nucleotide, as disclosed herein), may include advantageously promote BAT levels, decrease lipogenesis in adipose cells, decrease hepatic steatosis, or any combination of the foregoing.

(82) As disclosed herein, in an example, contacting cells of an organism with a nucleotide sequence including a Ucp1 cis-regulatory element neighboring a Vgll4 coding sequence surprisingly increases BAT volume, i.e. the volume occupied by BAT cells. In another example, contacting cells of an organism with a nucleotide sequence including a Ucp1 cis-regulatory element neighboring a

Vgll4 coding sequence surprisingly decreases WAT volume. In another example, contacting cells of an organism with a nucleotide sequence including a Ucp1 cis-regulatory element neighboring a Vgll4 coding sequence surprisingly increases a ratio of BAT volume to WAT volume. An increase in BAT by driving Vgll4 expression under control of a Ucp1 cis-regulatory element, known to increase expression of a neighboring gene in BAT cells, is particularly unexpected given that increased Vgll4 expression is known to promote apoptosis or otherwise have anti-tumor cell effects, unlike other members of the Vgll family. By comparison, Vgll3 levels are increased in WAT cells in obese mice, suggesting that Vgll3 may promote WAT cells, whereas over-expression of Vgll3 inhibits adipogenesis overall. U.S. Pat. No. 8,852,939.

(83) As further disclosed herein, in an example, contacting cells of an organism with a nucleotide sequence including a Ucp1 cis-regulatory element neighboring a Vgll4 coding sequence or a Vgll4-HF4A sequence in some cases may promote expression of Vgll4 or Vgll4-HF4A respectively, in liver.

(84) In another example, contacting cells of an organism with a nucleotide sequence including a Ucp1 cis-regulatory element neighboring a Vgll4-H1F4A coding sequence may surprisingly decrease adipose tissue volume. In an example, a volume of BAT is decreased. Without limiting the present disclosure to any particular mechanism of action, decreased volume of BAT following transfection with such a construct may be related to stimulation of expression of mitochondrial genes involved in mitochondrial respiration, inhibition of expression of genes involved in lipogenesis, an inhibition of lipogenesis, or any combination of two or more of the foregoing, in BAT, caused by the transfection. In another example, hepatic steatosis is decreased. Without limiting the present disclosure to any particular mechanism of action, decreased hepatic steatosis following transfection with such a construct may be related to stimulation of expression of mitochondrial genes involved in mitochondrial respiration, inhibition of expression of genes involved in lipogenesis, an inhibition of lipogenesis, or any combination of two or more of the foregoing, in liver, caused by the transfection.

## EXAMPLES

(85) The following examples are intended to illustrate particular embodiments of the present disclosure, but are by no means intended to limit the scope thereof.

**Example 1: A Ucp1 Cis-Regulatory Element Drives Expression in BAT when Transfection Occurs During Early Development**

(86) FIG. 1 shows examples of polynucleotides in accordance with certain aspects of the present disclosure. The example includes a cis-regulatory element (BCE) including a mouse Ucp1 enhancer and mouse Ucp1 promoter upstream of a coding sequence of a reporter protein (either a green fluorescent protein (GFP) or firefly luciferase (Luci)). In these examples, a chimeric intron of human  $\beta$ -globin and immunoglobulin heavy chain genes is included between the BCE and the reporter sequence. Inclusion of an intron may increase expression of the payload gene sequence, here the reporter constructs. Also included at the 5' and 3' ends, flanking the BCE and reporter, are inverted terminal repeat (ITR) sequences. Adeno-associated viral vectors were synthesized incorporating constructs as illustrated for determining an ability of BCE to drive expression of a downstream coding sequence. In an example, adeno-associated viral vectors of serotype 9 (AAV9) were constructed carrying constructs as illustrated in FIG. 1. Constructs include a BCE having a sequence of SEQ ID NO: 3 and an intron of SEQ ID NO: 34.

(87) FIG. 2 illustrates time course of treatment of mice with a viral vectors as illustrated in FIG. 1 for determining expression patterns of reporter proteins driven by BCE. At 5 days of age (P5), neonatal mice received dorsal sc AAV injection (of an AAV9 carrying one of the constructs shown in FIG. 1), at a dose of  $1 \times 10^{10}$  genome copies per gram of body weight, in phosphate-buffered saline. At 42 days after birth (P42), bioluminescence was assessed to determine expression of marker proteins. Expression was determined by an in vivo imaging system (IVIS™, Perkin Elmer) as shown in FIG. 3 (dorsal view) and 4 (ventral view), as well as by micro CT scanning to show

topographical expression patterns, as shown in FIG. 5. AAV9.BCE.luci transduced subjects were first imaged for bioluminescence, and then scanned by micro CT, with AAV9.BCE.GFP serving as a control. In FIG. 5, bioluminescence signal origins were matched with tissues mapped by micro CT (pink=brown adipose tissue, blue or red=bioluminescence signal positive tissues). Expression was specifically elevated in BAT, demonstrating the BAT-specific expression driven by the BCE cis-regulatory element following transfection during the neonatal period.

(88) As shown in FIGS. 6 and 7, interscapular adipose tissues (i.e., in the region where BAT is located) were collected at postnatal day 60 and used for immunofluorescence staining. FIG. 6 shows immunofluorescence staining images of interscapular BAT (using UCP1 imaging to identify BAT cells), and FIG. 7 shows immunofluorescence staining images of both BAT and white adipose tissue (using perilipin staining to mark adipose tissue, both BAT and WAT). Nuclear stain DAPI is also shown in FIG. 6 and GFP expression was used to stain cells with BCE-driven reporter expression in animals treated with AAV.BCE.GFP (with AAV.BCE.Luci treatment serving as control). Bar=200  $\mu$ m. BCE drove expression of reporter protein in adipocytes, and in BAT in particular.

(89) FIG. 8 shows a schematic view of a pAAV.BCE.Vgll4-GFP construct administered via an AAV9 carrier. The construct resembles that shown in FIG. 1 except that Vgll4-GFP is the coding sequence whose expression is driven by BCE rather than merely GFP or luciferase. The sequence of the BCA-intron-Vgll4-GFP transcript is SEQ ID NO:39, and is a polynucleotide including a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein, wherein the cis-regulatory element includes an uncoupling protein 1 enhancer and an uncoupling protein 1 promoter. An intron is present between the cis-regulatory element and nucleotide sequence encoding a vestigial like 4 protein. The construct was packaged in an adeno-associated viral vector (AAV9) for transfection of cells of an organism with the construct.

(90) FIG. 9 illustrates time course of treatment of mice with a viral vectors as illustrated in FIG. 8 for determining effects on adipose tissue volume. On postnatal day 5 mice were injected dorsally sc with AAV (AAV9.BCE.Vgll4-GFP, or AAV9.BCE.GFP, carrying the construct shown in FIG. 1, as a control), at a dose of  $1 \times 10^{10}$  genome copies per gram of body weight, in phosphate-buffered saline. On postnatal day 42, a micro CT scan was taken to measure intrascapular adipose tissue volume, using standard commercially available micro CT scan software (analyze 12<sup>TM</sup>).

Intrascapular adipose tissue was differentiable from neighboring tissue, and BAT was differentiable from WAT, due to differences in Hounsfield units associated with differing tissue types according to standard micro CT scan techniques. An example scan is shown in FIG. 10 (control) and 11 (for a subject injected with AAV9.BCE.Vgll4-GFP). BAT and WAT are as indicated. Increased volume of BAT and decreased volume of WAT can be seen following BCE-driven expression of Vgll4.

(91) BAT volume was measured as graphically represented in FIG. 12. In subjects with BCE-driven Vgll4 expression, BAT volume was an average of  $102.2 \pm 2.8$  mm.sup.3, compared to  $84.2 \pm 1.9$  mm.sup.3 in controls (\*= $p < 0.05$ ). WAT volume was measured as graphically represented in FIG. 13. In subjects with BCE-driven Vgll4 expression, WAT volume was an average of  $27.1 \pm 0.6$  mm.sup.3, compared to  $40.0 \pm 2.8$  mm.sup.3 in controls (\*\*= $p < 0.01$ ). Ratio of BAT/WAT volume was measured as graphically represented in FIG. 14. In subjects with BCE-driven Vgll4 expression, BAT/WAT volume ration was an average of  $3.8 \pm 0.6$  mm.sup.3, compared to  $40.0 \pm 2.8$  mm.sup.3 in controls (\*\*= $p < 0.01$ ). Thus, transfection of cells of an organism with a construct including a cis-regulatory element driving expression of Vgll4, wherein the cis-regulatory element includes an uncoupling protein 1 enhancer and an uncoupling protein 1 promoter, increased BAT volume, decreased WAT volume, and increased a ration of BAT volume to WAT volume.

Example 2: A Ucp1 Cis-Regulatory Element Drives Expression in BAT and Liver when Transfection Occurs During Adulthood

(92) An AAV vector (AAV9) containing a construct with a BCE cis regulatory element (SEQ ID NO: 3) driving expression of luciferase (AAV.BCE.Luci) was administered to 6 weeks old mice. In

other mice, the cis regulatory element (MiniUcp1) included a Ucp1 enhancer (SEQ ID NO: 4) but not a Ucp1 promoter (AAV.MiniUcp1.Luci). Subjects were tested for luciferase signals one week later. Results are illustrated in FIGS. 15-18. Both BAT (FIG. 16) and liver (FIG. 17) had luciferase signals, with BCE cis regulatory element driving higher liver expression than MiniUcp1. AAV.BCE.Luci drives expression in liver when transfection occurs later in development such as in adulthood. FIG. 18 shows that BAT and liver included viral vector genome copies, as assessed by real-time PCR.

(93) AAV has very low chance of integrating into the host cell genome, existing primarily as episomes in host cells. If the host cells proliferate rapidly, daughter cells may easily lose AAV copy number. In cell cycle quiescent cells, in contrast, AAV coexist until cells die. During development, such as in neonates, hepatocytes are rapidly proliferating, whereas BAT are mostly cell cycle quiescent cells. Without being limited to any particular theory or mechanism of action, during the growth of AAV.BCE.Luci transduced pups, hepatocytes but not the brown adipocytes may have shed AAVs, which could explain why luciferase signals can only be detected in the BAT but not in the liver following transfection early in development (as in Example 1). In the AAV.BCE.Luci transduced adult mice of the present Example (Example 2), BAT and hepatocytes were not actively proliferating, and luciferase signals were detected in both tissues.

#### Example 3. The Hippo-YAP Pathway

(94) The Hippo-YAP signaling pathway is well known for controlling organ growth. In mammals, the Hippo kinase cascade includes MST1/2, LATS1/2, and the scaffold protein Salvador (Sav). Activation of these kinases results in phosphorylation and inactivation of YAP and WWTR1 (more commonly known as TAZ), orthologous transcriptional coactivators that are terminal effectors of this pathway. YAP/TAZ interact with TEAD family transcription factors to regulate downstream target genes expression. Vestigial like 4 (VGLL4) is another co-transcriptional factor that serves as a suppressor of a YAP-TEAD complex. Mechanistically, VGLL4 directly binds to TEAD through its two TONDU (TDU) domains, and the binding of VGLL4 or YAP to TEAD is mutually exclusive (FIG. 19).

(95) Each VGLL4 TDU domain has two essential amino acid residues (HF) mediating VGLL4-TEAD interaction (SEQ ID NO: 41 and SEQ ID NO: 42, respectively). Replacing the HFs in the TDU domains with four alanine residues (FIG. 20) minimizes the interaction between VGLL4 and TEAD. Unlike VGLL4, VGLL4-HF4A does not suppress a YAP-TEAD complex (FIG. 21). YAP/TAZ may promote BAT thermogenesis, raising the possibility of manipulating this pathway to reduce obesity.

#### Example 3. TEAD1 Directly Regulates the Expression of Fgf21

(96) Double heterozygous YAP and TAZ knockout mice have previously been shown to have much smaller BAT than their littermate controls at four weeks after birth. In the Hippo-YAP pathway, YAP/TAZ interacts with TEAD proteins to regulate downstream targets expression. Thus, TEAD1 may regulate the postnatal growth of BAT. As disclosed herein, Ucp1::Cre transgenic mice were crossed with Tead1 flox allele to specifically delete Tead1 in the BAT (FIG. 22). TEAD1 depletion in BAT of Tead1 cKO mice was confirmed by western blot (FIG. 23). Compared with controls, the Tead1 cKO mice had smaller interscapular BAT deposits (FIGS. 24 and 25). Knocking out TEAD1 in the brown adipocytes significantly decreased the expression of Fgf21 in BAT (FIG. 26).

Chromatin immunoprecipitation sequencing data demonstrated that TEAD1 directly binds to the promoter region of Fgf21 (FIG. 27). Fibroblast growth factor 21 (FGF21) is an important myokine that regulates glucose-lipid metabolism.

#### Example 4. Activation of VGLL4 Reduces Adiposity

(97) BAT plays important roles in non-shivering thermogenesis and energy homeostasis. As disclosed herein, AAV-mediated overexpression of VGLL4 increased BAT volume. To demonstrate whether activation of VGLL4 in an obesity model (mice fed on a high fat diet) would reduce body weight, AAV.BCE.VGLL4 (including SEQ ID NO: 39) into high fat diet induced obesity mice, and

their body weight monitored for 7 weeks (FIG. 28). Controls received AAV with luciferase controlled by the cis regulatory element (SEQ ID NO: 3). 8 weeks after AAV delivery, luciferase signals were easily detected in the AAV.BCE.luci transduced mice (FIG. 29). Body weight and body weight gain values were not distinguishable between control and VGLL4 treated mice (FIGS. 30 and 31). However, using micro CT, the volume of adipose and non-adipose tissue (lean mass) were measured. 4 weeks after AAV transduction, although the body weight gain was similar between control and VGLL4 mice, the control but not the VGLL4 mice showed a significantly increase in adipose tissue mass. Meanwhile, VGLL4 but not the control mice had a significant increase of lean mass. Consequently, 4 weeks after AAV infusion, the VGLL4 mice had a lower fat/lean test ratio than the control mice (FIGS. 32A-C). Western blot showed that exogenous VGLL4 was expressed in BAT of AAV.BCE.VGLL4 transduced mice (not shown).

#### Example 5. AAV.BCE.VGLL4 Mitigates Body Weight Gain

(98) To demonstrate whether activation of VGLL4 in normal mice would prevent or mitigate the progression of obesity, AAV.BCE.VGLL4 (including SEQ ID NO: 39) was administered to 8-week-old mice. Beginning 1 week after injection, mice were fed a high-fat diet (FIG. 33A). At the end of 13 weeks high fat diet treatment, the body weight of VGLL4 mice was lower than the control mice, though the difference did not reach statistical significance (FIG. 33B). Starting from week 5, however, VGLL4 mice had a significantly lower accumulated body weight gain than controls (FIG. 33C). As disclosed herein (Example 2), AAV.BCE.VGLL4 targets both BAT and liver when administered later in development such as in adulthood. Fgf21 is a target of TEAD1 (FIGS. 26 and 27), and is mainly produced by liver and adipose tissue. Expression of VGLL4 and Fgf21 was therefore measure in liver. VGLL4 was overexpressed in liver, and that Fgf21 was significantly decreased in liver of VGLL4 mice (FIG. 33D).

#### Example 6. AAV.BCE.VGLL4HF4A Increases BAT Mitochondrial Genes Expression

(99) As disclosed herein, VGLL4 expression driven by a Ucp1 cis regulatory element mitigated body weight gain, it also suppressed the expression of Fgf21, which is important for glucose metabolism. VGLL4 may therefore have multiple roles, interacting with TEAD1 to decrease Fgf21 expression, while also interacting with other unknown factors to improve energy expenditure. Without being limited to any particular theory or mechanism of action, this possibility may indicate why VGLL4 may mitigate body weight gain without improving glucose metabolism. An AAV.BCE.VGLL4HF4A vector was created, which expresses a mutated VGLL4 that does not interact with TEAD (H1F4A mutations), including SEQ ID NO: 36, and also including a GFP reporter protein (SEQ ID NO: 40). 8-week-old normal mice received subcutaneous injection of AAV.BCE.VGLL4HF4A, resulting in transfection of BAT (FIG. 34A and B). qRT-PCR results showed that over-expression of VGLL4HF4A did not affect the expression of Fgf21 but reduced the expression of Cidea and Fasn (FIG. 34C), which are two genes involved in lipogenesis, in BAT. Additionally, VGLL4HF4A increased the expression of Cox2 (Cytochrome C Oxidase Subunit II, encoded by MT-CO2) and Cox6a2 (Cytochrome C Oxidase Subunit 6A2) in BAT (FIG. 34D). These data indicate that VGLL4HF4A may increase mitochondrial respiration activity without affecting Fgf21 expression, and also reduce lipogenesis.

#### Example 7. AAV.BCE.VGLL4HF4A Mitigates Body Weight Gain and Reduces Serum Glucose Level

(100) AAV.BCE.VGLL4HF4A (including SEQ ID NO: 36) was injected sc to the inter-scapular region of 8 week old C57/BL6 mice, at a dosage of  $2 \times 10^8$  GC/gram body weight. AAV.BCE.GFP was used as control. One week after virus injection, 12 weeks of feeding with high fat diet (HFD) began (FIG. 35A). During HFD treatment, body weight gain rate of AAV.BCE.VGLL4HF4A mice (VGLL4HF4A) was slower than that of the AAV.BCE.GFP mice, and the difference reached to significance at 9 weeks after HFD treatment (FIG. 35B). 11 weeks after high fat diet treatment, the body weight of AAV.BCE.VGLL4HF4A mice started to become significantly lower than that of the AAV.BCE.GFP mice (FIG. 35C). A glucose tolerance test (GTT)



showed that the starving serum glucose level and glucose peak level following glucose challenge was significantly lower in the AAV.BCE.VGLL4HF4A mice (FIG. 35D).

#### Example 8. AAV.BCE.VGLL4HF4A Reduces BAT Weight

(101) Compared to that of the GFP control mice, the mass of BAT was significantly lower in the VGLL4HF4A mice (FIG. 36A). qRT-PCR confirmed that VGLL4 was overexpressed in the BAT of VGLL4HF4A mice (FIG. 36B). The expression of Ucp1 was not affected by VGLL4HF4A (FIG. 36C). Expression levels of three more genes that regulate mitochondria respiration activity were also measured in BAT: Cox2, Cox6a, Ndufa8. Cox2 was significantly upregulated in the VGLL4HF4A BAT (FIG. 36D). VGLL4HF4A also suppressed expression of Acc1, a gene involved in fatty acid synthesis (FIG. 36E). VGLL4HF4A may therefore preserve BAT function by both increasing the mitochondria respiration activity and attenuating fatty acid synthesis.

#### Example 9. AAV.BCE.VGLL4HF4A Reduces Liver Weight and Fatty Acid Synthesis

(102) A BCE cis regulatory element including a Ucp1 enhancer and Ucp1 promoter as disclosed herein drives gene expression in liver when adult subjects are transfected, as disclosed herein. Interestingly, liver weight of VGLL4HF4A mice was significantly lower than that of the GFP control mice (FIG. 37A). qRT-PCR confirmed that VGLL4 was robustly overexpressed in liver of VGLL4HF4A mice (FIG. 37B). Histology determined by haematoxylin and eosin (H&E) staining showed moderate lipid droplets accumulation and microsteatosis (FIG. 37C). Oil red staining confirmed that VGLL4HF4A liver had much less lipid droplets accumulation than the GFP control liver (FIG. 37D). The expression of fatty acid synthesis genes Acc1 and Fasn in liver were significantly reduced by VGLL4HF4A (FIG. 37E). VGLL4HF4A may prevent HFD induced liver pathologies such as liver metabolic dysfunction, inflammation, or nonalcoholic fatty liver disease (103) It should be appreciated that all combinations of the foregoing concepts and additional concepts discussed in greater detail herein (provided such concepts are not mutually inconsistent) are contemplated as being part of the inventive subject matter disclosed herein. In particular, all combinations of claimed subject matter appearing at the end of this disclosure are contemplated as being part of the inventive subject matter disclosed herein and may be used to achieve the benefits and advantages described herein.

(104) Although examples have been depicted and described in detail herein, it will be apparent to those skilled in the relevant art that various modifications, additions, substitutions, and the like can be made without departing from the spirit of the present disclosure and these are therefore considered to be within the scope of the present disclosure as defined in the claims that follow.

## Claims

1. A method, comprising administering a polynucleotide to a subject, wherein the polynucleotide comprises: a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein, wherein the cis-regulatory element comprises an uncoupling protein 1 enhancer and an uncoupling protein 1 promoter, and the vestigial like 4 protein comprises a first TDU domain having a first amino acid sequence and a second TDU domain having a second amino acid sequence, wherein the first amino acid sequence comprises the amino acid sequence as set forth in SEQ ID NO: 41 with two amino acid substitutions, wherein the seventh amino acid of the amino acid sequence as set forth in SEQ ID NO: 41 is not H and the eighth amino acid of the amino acid sequence as set forth in SEQ ID NO: 41 is not F, and the second amino acid sequence comprises the amino acid sequence as set forth in SEQ ID NO: 42, wherein the seventh amino acid of the amino acid sequence as set forth in SEQ ID NO: 42 is not H and the eighth amino acid of the amino acid sequence as set forth in SEQ ID NO: 42 is not F.
2. The method of claim 1, wherein the uncoupling protein 1 enhancer has at least 90% identity with a sequence selected from SEQ ID NO: 1, SEQ ID NO 4, and SEQ ID NO: 7.
3. The method of claim 1, wherein the uncoupling protein 1 promoter has at least 90% identity with

- a sequence selected from SEQ ID NO: 2, SEQ ID NO 5, and SEQ ID NO: 8.
4. The method of claim 1, wherein the cis-regulatory element has at least 90% homology with a sequence selected from SEQ ID NO: 3, SEQ ID NO: 6, and SEQ ID NO: 9.
  5. The method of claim 1, wherein the vestigial like 4 protein has at least 90% homology with a sequence selected from SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, and SEQ ID NO: 33.
  6. The method of claim 1, wherein the sequence encoding a vestigial like 4 protein has at least 90% identity with a sequence selected from SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, and SEQ ID NO: 32.
  7. The method of claim 1, wherein the vestigial like 4 protein has from 0 to 3 substitutions to a sequence selected from SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, and SEQ ID NO: 33, wherein the substitutions are not in the first TDU domain or the second TDU domain.
  8. The method of claim 1, wherein the polynucleotide further comprises an intron between the cis-regulatory element and the nucleotide sequence encoding a vestigial like 4 protein.
  9. The method of claim 8, wherein the intron has at least 90% homology with SEQ ID NO: 34.
  10. The method of claim 1, wherein the administering comprises administering a viral vector, and the viral vector comprises the polynucleotide.
  11. The method of claim 10, wherein the viral vector is comprises an adenoviral associated vector.
  12. The method of claim 10, wherein the uncoupling protein 1 enhancer has at least 90% identity with a sequence selected from SEQ ID NO: 1, SEQ ID NO 4, and SEQ ID NO: 7.
  13. The method of claim 10, wherein the uncoupling protein 1 promotor has at least 90% identity with a sequence selected from SEQ ID NO: 2, SEQ ID NO 5, and SEQ ID NO: 8.
  14. The method of claim 10, wherein the cis-regulatory element has at least 90% homology with a sequence selected from SEQ ID NO: 3, SEQ ID NO: 6, and SEQ ID NO: 9.
  15. The method of claim 10, wherein the vestigial like 4 protein has at least 90% homology with a sequence selected from SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, and SEQ ID NO: 33.
  16. The method of claim 10, wherein the sequence encoding a vestigial like 4 protein has at least 90% identity with a sequence selected from SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, and SEQ ID NO: 32.
  17. The method of claim 10, wherein the vestigial like 4 protein has from 0 to 3 substitutions to a sequence selected from SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, and SEQ ID NO: 33, wherein the substitutions are not in the first TDU domain or the second TDU domain.
  18. The method of claim 1, wherein the subject is obese or is at risk for developing obesity.
  19. The method of claim 1, wherein the subject has hepatic steatosis or is at risk for developing hepatic steatosis.
  20. The method of claim 1, wherein the subject has diabetes or is at risk for developing diabetes.
-